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Summary
In the present thesis computational methods are employed to study actin, a protein constituting
a major component of the eukaryotic cytoskeleton. Actin is an interesting drug target for
the treatment of cancer since organization and polymerization state of the actin network are
malignantly modified in tumor cells. Moreover, a local disruption of the actin cytoskeleton has
been recognized as a promising addition to the methods of treating glaucoma. However, all
known actin-targeting small molecules are natural products or close analogues with complex
chemical structures, which are difficult to synthesize or to gather from natural sources such
as marine sponges. As a consequence there is a need for novel chemical structures as lead
compounds targeting actin.
Different computational approaches aimed at identifying actin-binding compounds are used
in this thesis. The first method is virtual screening, the most commonly used approach to
hit identification in computer-aided drug discovery, which is based on docking and ranking a
large collection of compounds. Here, a library of small molecules obtained by decomposing
natural products is screened since natural products have been selected by natural evolution to
interact with biological targets such as proteins. Therefore, a natural product-inspired library
is expected to be enriched in biological activity. The hits obtained by the virtual screening
campaign are validated using explicit water molecular dynamics (MD) simulations. The binding
mode of compounds with a high binding affinity is expected to be stable in multiple MD runs
on a nanosecond time scale. Several molecules with a promising binding behavior in the MD
simulations are suggested for chemical synthesis and in vitro binding assays. The stability of one
hit is significantly improved by in silico optimization based on the most populated structural
clusters obtained from the MD runs.
De novo design is employed as a second approach to identify novel actin-targeting small
molecules. The unique thiazolidinone ring of latrunculin is used as an anchor for the attachment
of additional fragments to exploit the optimal hydrogen bond forming properties of this moiety
for the actin binding site.
Lastly, MD simulations are carried out to elucidate the mechanism by which latrunculin
inhibits actin polymerization. It is shown that latrunculin prevents conformational changes
necessary to the transition from monomeric to filamentous actin.
I
Zusammenfassung
In der vorliegenden Dissertation werden computergestu¨tzte Methoden zur Untersuchung des
Proteins Aktin angewandt, ein wichtiger Bestandteil des Zytoskeletts. Aktin stellt ein in-
teressantes Drug-Target (Zielmoleku¨l) fu¨r die Behandlung von Krebs dar, da die Organisa-
tion und der Polymerisationsgrad des Aktinnetzwerks in Tumorzellen bo¨sartig vera¨ndert ist.
Des Weiteren wurde die lokale Zersto¨rung des Aktinzytoskeletts als vielversprechende neue
Methode zur Behandlung von gru¨nem Star (Glaukom) erkannt. Bei allen bekannten Aktin-
bindenden Moleku¨len handelt es sich jedoch um Naturstoffe oder verwandte Analoga mit kom-
plexer chemischer Struktur, die schwer zu synthetisieren oder aus natu¨rlichen Quellen wie mari-
nen Schwa¨mmen zu gewinnen sind. Aus diesem Grund existiert ein Bedarf an neuartigen
chemischen Strukturen fu¨r Leitwirkstoffe, die auf Aktin abzielen.
Verschiedene computergestu¨tzte Ansa¨tze werden in dieser Dissertation zur Identifikation
neuer Aktin-bindender Verbindungen benutzt. Bei dem ersten Ansatz handelt es sich um
virtuelles Screening, die am ha¨ufigsten verwendete Methode zur Hit-Identifikation im comput-
ergestu¨tztenWirkstoffdesign, die auf dem Docking und Ranking von großen Moleku¨lbibliotheken
basiert. In dieser Arbeit wird eine Bibliothek aus Moleku¨len gescreent, die durch Zerlegung von
Naturstoffen erhalten wurden, da Naturstoffe durch natu¨rliche Evolution entsprechend ihrer
Fa¨higkeit zur Interaktion mit Biomoleku¨len wie Proteinen selektiert wurden. Aus diesem
Grunde ist eine Naturstoff-basierte Bibliothek vermutlich angereichert an Strukturen mit bi-
ologischer Aktivita¨t. Die durch virtuelles Screening erhaltenen Hits werden mit Hilfe von
Moleku¨ldynamik- (MD-) Simulationen unter expliziter Beru¨cksichtigung des Lo¨sungsmittels va-
lidiert. Fu¨r Verbindungen mit hoher Bindungsaffinita¨t wird erwartet, dass die Bindungsmoden
im Nanosekunden-Maßstab stabil sind. Einige Moleku¨le mit vielversprechendem Bindeverhalten
in den MD-Simulationen werden fu¨r chemische Synthese und Untersuchung der Bindungsaffinita¨t
durch in vitro Bindungsassays vorgeschlagen. Die Stabilita¨t eines Hits konnte durch comput-
ergestu¨tzte Optimierung stark verbessert werden, die auf den am meisten populierten struk-
turellen Clustern der MD-Simulationen basiert.
Bei der zweiten angewandten Methode zur Identifikation neuartiger Aktin-bindender Moleku¨le
handelt es sich um De Novo-Design. Der einzigartige Thiazolidinon-Ring des Aktin-Inhibitors
Latrunculin wird als Ankerfragment zur Addition weiterer Fragmente verwendet, um seine op-
timale Fa¨higkeit zur Ausbildung von Wasserstoffbru¨ckenbindungen in der Aktin-Bindetasche
II
auszunutzen.
Schließlich werden MD-Simulationen zur Aufkla¨rung des Mechanismus durchgefu¨hrt, mit
dem Latrunculin die Polymerisation von Aktin inhibiert. Es wird gezeigt, dass Latrunculin
Konformationsa¨nderungen verhindert, die notwendig fu¨r den U¨bergang von monomerem zu
polymerem Aktin sind.
III
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Chapter 1
Introduction
1.1 The Target: Actin
1.1.1 Actin as a Major Constituent of the Cytoskeleton
The first electron micrographs of cells gave the impression that cells consist of organelles float-
ing freely in a gel-like medium called cytosol. [1] By improved light and electron microscopy
techniques it was later discovered that the cytosol is pervaded by a network of filaments, the
cytoskeleton. Together cytosol and cytoskeleton make up the cytoplasm of a cell. The cy-
toskeleton consists of three types of filaments: microtubules, microfilaments, and intermediate
filaments. The cytoskeletal filaments differ in size and the type of protein they are composed of.
Microtubules consist of the protein tubulin and constitute the thickest cytoskeletal filaments,
with an average diameter of 25 nm. Intermediate filaments have a diameter of 10 nm and con-
sist of a variety of different proteins, most of which belong to the keratin family. The thinnest
filaments are the microfilaments with a diameter of 5-7 nm. They consist of actin, the most
abundant protein in many eukaryotic cells. [2,3] As a main constituent of the cytoskeleton, actin
is of fundamental importance for various cellular functions such as cell division, morphology,
motility, cytokinesis, adhesion, and muscle contraction. Due to its crucial role for the func-
tioning of cells, its amino acid sequence and structure are highly conserved. The monomeric
form (G-actin) assembles to the biologically active filamentous structure (F-actin) in the form
of double-stranded helices. The dynamic equilibrium between assembly and disassembly leads
to a continuous rearrangement of the actin cytoskeleton, a process controlled by a variety of
actin-regulating proteins. Examples of actin-binding proteins are profilin and DNase I which
both bind to monomers, the filament-capping and -severing gelsolin, and cofilin which severs
filaments and accelerates depolymerization at the pointed end. [4]
Actin is involved in cell movement, usually in association with the motor protein myosin.
In the contractile apparatus of muscle cells, actin filaments are arranged in parallel rows, and
the space in between is filled with myosin filaments, an arrangement called a myofibril. A
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contraction of the muscle cell occurs when actin and myosin filaments slide past each other, a
process caused by conformational changes of myosin driven by ATP. [1]
Interactions of actin and myosin are, however, not only responsible for the contraction of
muscles, but also for movements of nonmuscle eukaryotic cells such as the crawling motion of
cells across a surface. Moreover, F-actin acts as “tracks” for the transport of organelles and
vesicles within eukaryotic cells, which is based on myosin sliding along the actin filaments. [1]
The actin cytoskeleton is manipulated by a wide range of bacterial and viral human pathogens
such as Salmonella. [5] A variety of different mechanisms exist by which microbial pathogens ex-
ploit the actin cytoskeleton of a host cell to promote infection. One example is an increase in cell
motility by changing normal actin organization and dynamics, thereby facilitating propagation
of the pathogen.
1.1.2 Structure of G-actin
G-actin has a molecular weight of 42 kDa and consists of 375 residues. The three dimensional
structure of G-actin is relatively flat. The single polypeptide chain folds around a deep cleft,
the nucleotide binding site, into two domains of similar size which are commonly subdivided
into four subdomains (see chapter 4, Fig. 1). Based on the characteristics of its fold, actin is
allocated to the same superfamily as hexokinases, sugar kinases, Hsp70 proteins, Arp proteins,
and the prokaryotic actin-like homologues MreB and ParM. [6]
Subdomain 2 contains the most mobile part of actin, the DNase I binding loop (D-loop),
whose coordinates are not resolved in many crystal structures due to its high flexibility. Both
N- and C-terminus lie in subdomain 1. Since the G-actin crystal structure was first solved in
1990 [7], more than 80 different crystal structures have been published of G-actin in complex
with different nucleotides, actin-binding proteins, or small molecules such as latrunculin. In all
G-actin crystal structures the two domains are arranged in a propeller-like twist relative to each
other.
1.1.3 Filament structure and dynamics
The two ends of an actin filament exhibit different structural and dynamical properties, which
has important implications for the dynamic equilibrium between G-actin and F-actin and fila-
ment organization. Due to a higher polymerization rate at the barbed or plus (+) end, a net
elongation of the filament occurs, while the pointed or minus (-) end has a higher dissocia-
tion than association rate causing a net depolymerization and shortening of the filament at the
pointed end. This phenomenon is called “treadmilling” because a monomer incorporated into
the filament at the barbed end apparently “moves” through the polymer to the pointed end
as if it were on a treadmill. Treadmilling constitutes the basic mechanism of cell motility by
reorganization of the actin cytoskeleton. [8]
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The energy required for actin polymerization is supplied by the ATP molecule bound within
the deep cleft between the two domains of G-actin. ATP is hydrolyzed after incorporation of
the monomer unit into F-actin with a half time of about 2 s. [9] The subsequent release of the
inorganic phosphate is an even slower process with a half time of a few minutes. The slow rates
lead to the existence of three structurally and functionally different regions in an actin filament:
an ATP region at the growing barbed end, an intermediary ADP-Pi region, and an ADP region
at the shrinking pointed end (Fig. 1.1). The nature of the nucleotide affects the conformation of
the actin subunit it is bound to, and is an important modulator of the binding affinity of actin-
regulating proteins to the filament. ADP-actin has a much lower tendency to polymerize than
ATP-actin. Profilin promotes nucleotide exchange of ADP-actin, and the resulting ATP-actin
can again be incorporated into an actin filament.
ATP-actin
ADP-Pi-actin
ADP-actin
nucleotide exchange
barbed (+) end pointed (-) end
Pi
Figure 1.1: Schematic picture of actin filament dynamics. Due to the slow hydrolysis of ATP
and even slower release of inorganic phosphate, F-actin consists of an ATP region (blue), an
ADP-Pi region (green), and an ADP region (gray).
Due to the difficulties associated with the crystallization of actin filaments, the exact struc-
ture of F-actin remains to be determined. [6] The first F-actin model was constructed by Holmes
after the solution of the G-actin crystal structure in 1990. [7] The model was based on low-
resolution X-ray fiber diffraction data. In the following years, several refined F-actin models
were published, based on different techniques such as a directed mutation algorithm [10] and
normal mode analysis [11]. An important step towards elucidating the structure of the actin
filament was achieved by Oda et al. in 2009 [12], who designed a model based on X-ray fiber
diffraction data with a resolution of 3.3 A˚ in the radial direction and 5.6 A˚ along the equator.
The model revealed that a monomer subunit undergoes a significant conformational change
when incorporated into the filament, an interdomain rotation of about 20 degrees resulting in
a flattening of the monomer subunit. The flattening was confirmed by cryo-EM [13, 14] and a
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recently published refined F-actin model by Holmes et al. [15]. A schematic illustration of the
interdomain rotation is shown in Fig. 1.2.
Figure 1.2: Schematic illustration of the conformational change of an actin subunit in the G- to
F-actin transition. The twist of the two major domains relative to each other is flattened by an
interdomain rotation. The picture is taken from R. Dominguez and K. C. Holmes Annu. Rev.
Biophys. 2011, 40:169-186.
In chapter 4 the influence of the natural product latrunculin on the interdomain rotation
associated with the G- to F-actin transition is investigated.
1.1.4 Actin-targeting Small Molecules as Potential Drugs
Drugs designed to modify the actin cytoskeleton have been recognized as promising therapeutic
agents against different diseases such as cancer and glaucoma. [16–20] In tumor cells the molec-
ular organization and composition of the actin cytoskeleton is substantially transformed. As
these alterations are directly related to abnormal growth, invasion, and metastasis of malignant
cells, actin constitutes a potential target against cancer. Drugs modulating actin polymerization
could partially reverse the changes to the actin cytoskeleton in tumor cells and prevent further
tumor growth and progression. [21]
The major drawback of any actin-targeting drug that cannot distinguish between normal
and malignantly modified actin is the likely occurrence of substantial side effects. However, this
argument could also be applied to a few common chemotherapy drugs such as Taxol (paclitaxel).
Taxol targets the microtubule cytoskeleton and is unable to distinguish between microtubules
in normal and in tumor cells, but is still a useful anticancer agent because malignant cells
divide faster and consequently are more sensitive to mitotic inhibition than normal cells. Actin-
targeting drugs which accumulate faster in tumor cells could therefore significantly reduce side
effects.
4
1.2. COMPUTATIONAL METHODS CHAPTER 1. INTRODUCTION
A variety of natural products from different sources such as fungus and marine sponges have
been shown to target the actin cytoskeleton. [21] Compounds binding to the barbed end are
numerous and structurally diverse. Many have a long “tail” connected to a macrolide ring, such
as swinholide A and jasplakinolide. The only class of molecules binding to the pointed end are
latrunculins, the most potent naturally occurring representative of which is latrunculin A. [22,23]
The influence of latrunculin A on the dynamical properties of actin is the focus of chapter 4.
Latrunculins have strong anticancer effects, and latrunculins with a reduced binding affinity
to actin have been identified which show substantial anti-migratory and anti-invasive activity
without being cytotoxic. [24] In addition to their potential as lead structures, actin-targeting
natural products are frequently used as molecular probes to dissect cellular pathways. [21]
Due to its ability to reduce intraocular pressure by increasing aqueous humor outflow in
higher mammals, latrunculin is a promising lead compound for the treatment of glaucoma. [20]
Glaucoma is a disease of the eye in which vision is irreversibly lost, at least partly caused by
an increased intraocular pressure damaging the optic nerve. A local treatment with latrunculin
has been recognized as a promising antiglaucoma strategy: Latrunculin increases the outflow
facility of the eye by disrupting the actin cytoskeleton in the so-called trabecular meshwork, a
type of tissue located adjacent to the cornea, thereby reducing pressure on the optic nerve.
1.2 Computational Methods
1.2.1 De Novo Drug Design with GANDI
Computational approaches to drug design are valuable tools for the rational design of drugs. The
most commonly used method in computer-aided drug discovery is virtual screening, in which pre-
existing compounds are docked into a protein structure determined by X-ray crystallography,
NMR spectroscopy, or homology modeling. An interesting alternative is the construction of
ligands “from scratch”, an approach referred to as de novo design which is latin for “from
the beginning”. [25–27] It is less commonly used than virtual screening because the design of
potent binders which are synthetically accessible is a challenging task. A number of ways have
been proposed to deal with the issue of synthetic tractability, such as decomposing existing
molecules and recombining the resulting fragments according to a set of rules derived from
organic synthesis. [28]
The main advantage of de novo design over virtual screening is the much larger chemical
space accessible. Still, it is not feasible to evaluate all theoretically possible compounds because
chemical space is virtually infinite. [25]
An example of a de novo design program is GANDI (Genetic Algorithm-Based de Novo
Design of Inhibitors). [27] GANDI employs a genetic algorithm, i.e., an algorithm which mimics
Darwin’s theory of natural evolution. A population is evolved by mutation, cross-over, and
selection, and both the parent and children population compete for survival. In GANDI the
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genetic material of an individual consists of one chromosome with as many genes as fragments to
connect. A specific gene value corresponds to one docked fragment position and constitutes the
value to be optimized by the genetic algorithm. Several populations are evolved simultaneously
in GANDI, an approach called a “parallel” or an “island” genetic algorithm. The different
populations exchange genetic material after a specified number of steps. The newly introduced
genetic material helps to prevent premature convergence by allowing the algorithm to escape a
local minimum.
The docked fragments are connected by linker molecules. In contrast to the fragments, the
linkers are chosen and connected to the fragments by a random tabu search rather than a genetic
algorithm. The reason for decoupling the treatment of the fragments and the linkers is that
generally only few linkers are able to link two fragments. Including the choice of linkers in the
genetic algorithm would therefore increase computation time by exploring unfeasible regions of
search space.
Several scoring functions such as the force field energy, the 3D and 2D structural similarity,
and a pharmacophore scoring function are simultaneously optimized, an approach referred to as
multiobjective optimization. The individual scores can either be combined by a weighted-sum
or a Pareto-based method. The weighted-sum approach uses a linear combination of scoring
function terms:
Stotal = wffEff − w2DSim2D − w3DSim3D − wPH4SimPH4 (1.1)
where Stotal is the total score, Eff the force field energy, Sim2D and Sim3D the 2D and
3D similarity to a known ligand, and SimPH4 the pharmacophore score. The weights for the
scoring function terms are wff, w2D, w3D, and wPH4, respectively. The 2D structural similarity
is evaluated by the Tanimoto coefficient between 2D fingerprints.
Scaffold hopping can be promoted by using a high weight for the 3D similarity term, which
considers the spatial distribution of atoms of the binding mode of the known ligand, but not
its covalent structure. In the Pareto-based scoring an individual A dominates over another
individual B if the scores of all scoring functions of A are equal or lower (at least one) than the
corresponding scores of B. The advantage of a Pareto-based scoring is that it does not require
the tuning of any scoring function weights.
1.2.2 Molecular Dynamics Simulations
Introduction
Molecular dynamics (MD) simulations are a powerful tool to study structural and dynamical
properties of biomolecules. In contrast to more accurate, but computationally expensive quan-
tum mechanical methods, electrons are not treated explicitly in MD simulations. Instead, an
atomistic description is often employed which, in conjunction with the use of classical mechanics,
6
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renders MD simulations applicable to large biomolecules such as proteins or nucleic acids.
The first MD simulation was published in 1977 by McCammon et al. of the bovine pancreatic
trypsin inhibitor (BPTI) and was 9 ps long. [29] Today simulations in the microsecond time scale
are feasible due to substantial improvements in computer performance and the development of
more efficient algorithms. MD simulations complement experimental methods and can be used
to support and help to understand experimental results. In cases where the desired quantity
is not accessible by experimental methods, they offer an alternative way to investigate the
biological system or process of interest.
An MD simulation can be regarded as a virtual experiment where the atoms of a system
are allowed to propagate for a specified amount of time, and time-dependent processes are
monitored. A trajectory describing the propagation of the system over the course of time is
obtained by numerically integrating Newton’s equation of motion
Fi = −
∂U(x)
∂xi
= mix¨i (1.2)
where U is the potential energy of the system, and Fi, xi, and mi are the force, position, and
mass of atom i, respectively.
An important parameter to set in an MD simulation is the integration time step. The time
step has to be shorter than the highest atomic oscillation rate to be monitored. However, using
smaller time steps leads to higher computational costs. Chemical bonds involving hydrogens
have the highest oscillation rate, necessitating a time step of appr. one femtosecond. A fre-
quently used approximation is to fix the length of all bonds involving hydrogens, allowing for a
time step of about 2 fs to be used.
For biologically relevant time scales only empirical force fields are fast enough for MD
simulations of large biological systems such as proteins and nucleic acids. Empirical potential
energy functions, called molecular mechanics force fields, are used to describe the relationship
between structure and energy. Force fields constitute a compromise between accuracy and
computational cost. Different force field such as CHARMM [30], AMBER [31], GROMOS
[32], and OPLS [33] can differ both in mathematical form and set of empirical parameters.
Because electrons are not treated explicitly, bond formation and breaking processes cannot be
simulated by MD. A further approximation used in MD simulations with fixed-charge force
fields is neglecting charge polarization. In the CHARMM force field, the potential energy is
approximated by a sum of covalent and non-covalent energy contributions, where the former
is divided into a bond length, bond angle, dihedral angle, and improper dihedral angle term,
whereas the latter is described by a sum of a Coulombic potential to incorporate electrostatic
interactions and the Lennard-Jones potential to approximate van der Waals interactions:
U(R) =
∑
bonds
Kb(b− b0)
2 +
∑
angles
Kθ(θ − θ0)
2 +
∑
dihedrals
Kχ(1 + cos(nχ− δ))
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+
∑
impropers
Kimp(φ− φ0)
2 +
∑
nonbond

ij

(Rminij
rij
)12
− 2
(
Rminij
rij
)6+ qiqj
4pirij

 (1.3)
where Kb, Kθ, Kχ, and Kimp are the force constants for the bond, angle, dihedral, and improper
dihedral term, and b0, θ0, and φ0 the equilibrium values for the bond length b, angle θ, and
improper dihedral φ. In the dihedral angle term, n is the multiplicity, θ the dihedral angle and
δ the phase shift. In the non-covalent terms, Rminij is the distance between atoms i and j where
the Lennard-Jones potential is minimal, ij is the depth of the potential energy well, qi and qj
the charges of atoms i and j, and rij the distance between the two atoms.
Before an MD simulation can be carried out, the atom positions have to be energy-minimized.
In an X-ray structure some bonds can be stretched or shortened, and large forces would act on
the atoms if a simulation were started directly from such a structure, leading to an unphysical
acceleration of the atoms. To prevent this behavior, the net force acting on an atom, i.e., the
gradient of the potential energy with regard to the atomic positions, is brought to zero by
performing an energy minimization
Force Field Parameters for Druglike Molecules
One of the most commonly used empirical force fields is the CHARMM force field mentioned
above. Until recently, druglike molecules could not be simulated accurately due to the lack
of appropriate parameters in the CHARMM force field. In 2010 this issue was addressed by
the introduction of the CHARMM General Force Field (CGenFF). [34] The CGenFF contains
parameters for a wide range of chemical structures and functionalities commonly present in
druglike molecules such as heterocyclic moieties. It is fully compatible with the CHARMM22
force field.
For this thesis CGenFF parameters for putative actin inhibitors were assigned using the con-
venient ParamChem server (https://www.paramchem.org) which assigns CGenFF parameters
for an uploaded molecule.
Analysis of Molecular Dynamics Trajectories
Root Mean Square Deviation
The root mean square deviation (RMSD) between two conformations of a molecule is the
most commonly used measure of structural similarity, e.g. between a protein structure taken
from an MD snapshot and the corresponding crystal structure used as reference. Before com-
puting the RMSD, the structures to be compared have to be superimposed. For N atoms the
RMSD is defined as
8
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RMSD =
√√√√ 1
N
N∑
i=1
[
(xi − xref )2 + (yi − yref )2 + (zi − zref )2
]
(1.4)
where xi, yi, and zi are the coordinates of atom i in one structure, and xref , yref , and zref
the coordinates of atom i in the reference structure. Time series of RMSD from the crystal
structure are a useful measure of the overall structural stability of a protein over the course of
an MD simulation.
Root Mean Square Fluctuation
The RMSF constitutes a measure of atomic fluctuations and mobility observed in an MD sim-
ulation and is defined as
RMSFi =
√√√√ 1
n
n∑
j=1
[
(xi(j)− xref )2 + (yi(j)− yref )2 + (zi(j)− zref )2
]
(1.5)
for atom i, where the sum is over all n snapshots in a trajectory. The coordinates of atom i
in snapshot j are designated as xi(j), yi(j), and zi(j). In contrast to the RMSD where atomic
fluctuations are averaged over all atoms of a molecule for a specific point in time, the root
mean square fluctuation (RMSF) averages positional deviations of an atom over the course of
a simulation, yielding one RMSF value for each atom.
Motional Correlations of Atomic Fluctuations
Many of the biological functions proteins are involved in are related to correlated motions of
specific parts of the protein. The extent of correlation between atomic displacements can be
quantified by the normalized fluctuation correlation Cij between atom pairs averaged over the
snapshots of an MD simulation, an approach called dynamic cross correlation (DCC). [35,36] Cij
is defined as the normalized covariance between two atom position vectors, i.e., the covariance
between the vectors divided by the product of their standard deviations:
Cij =
(ri − ri)(rj − rj)√
(r2i − r
2
i )(r
2
j − r
2
j )
(1.6)
where ri and rj are the position vectors of atoms i and j, respectively. It is also possible to ex-
amine the motional correlation between entire residues. The normalized fluctuation correlation
ranges from Cij = 1 for full correlation, i.e., for atomic fluctuations with the same period and
same phase, through Cij = 0 for no correlation, to Cij = −1 for fully anticorrelated displace-
ments, i.e. for motions with the same period and opposite phase. The DCC method returns a
matrix of all pairwise normalized fluctuation correlations Cij which can be visualized in form of
a cross correlation map such as Fig. 4 in chapter 4. Since the diagonal represents the motional
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correlation between position vectors of the same atoms, the diagonal elements of the matrix
have to indicate full correlation. Normalized fluctuation correlations strongly depend on the
choice of atoms and reference frame for alignment prior to the correlation analysis. Note that
only linear correlations are captured by the DCC approach.
A second method to compute motional correlations is the linear mutual information (LMI)
approach. [36–38] The LMI algorithm is based on a different principle than the DCC method.
The LMI method measures how much information about a random variable A is contained in
a random variable B, i.e., how much information is shared by the two variables. The mutual
information between two random variables A and B is high when the uncertainty of B is reduced
by observing A. The LMI between the motions of two atoms i and j is calculated according to
Ilin(xi, xj) =
1
2
(ln|Ci|+ ln|Cj | − ln|Cij |) (1.7)
where Cij is the pair-wise covariance matrix, Ci and Cj are the marginal covariance matrices,
and xi and xj are the deviation of the positional fluctuations of atoms i and j from the mean
(xi = ri − ri and xj = rj − rj , respectively). LMI values vary from 0 indicating lack of any
correlation to +1, which is complete correlation between atomic displacements. Anticorrelation
is not captured by the mutual information measure.
The LMI method is computationally more expensive than the DCC approach, but the
former has the important advantage that it is able to capture correlations between perpendicular
motions. As the DCC method, the LMI approach is restricted to linear correlations, but a more
general MI (mutual information) algorithm exists which is able to detect nonlinear correlations
as well.
1.3 Structure of the Thesis
The identification of novel actin inhibitors is the focus of chapters 2 and 3. While virtual
screening and MD simulations are employed in chapter 2, de novo design is carried out in
chapter 3 to design truly novel actin inhibitors. In chapter 4 the influence of the natural
product latrunculin on the dynamic properties of G-actin is investigated by explicit water MD
simulations, elucidating the mode of action by which latrunculin prevents the polymerization
of actin. A summary of the results presented in this thesis and an outlook is given in the
Conclusion section.
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Chapter 2
Targeting G-actin by virtual
screening of a natural
product-inspired library and hit
validation by molecular dynamics
simulations
Abstract
Natural products constitute the part of chemical space selected by natural evolution to interact
with a wide range of biological targets with high binding affinity and selectivity. Compared to
standard compound collections, a natural product-inspired library is expected to be enriched in
molecules possessing the chemical properties necessary for binding to proteins, thereby facili-
tating the discovery of novel therapeutic agents. Here, we present a virtual screening campaign
of a natural product-derived library to identify compounds targeting actin. Actin inhibitors
are promising candidates for the development of novel anticancer and antiglaucoma drugs. To
obtain a more accurate ranking and validate the hits obtained by high-throughput docking and
reranking by consensus scoring, the stability of the binding modes of selected compounds is ex-
amined by explicit water molecular dynamics simulations. Several molecules with a promising
binding behavior in the simulations are suggested for chemical synthesis and in vitro binding
assays. Addition of only two heavy atoms to one of the hits significantly improved the stabil-
ity of the most populated binding mode, suggesting a higher binding affinity of the derivative
compared to the original compound.
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Introduction
Natural products (NPs) constitute a valuable source of novel chemical structures in the search
for new therapeutic agents. [1,2] Under evolutionary pressure they have been selected by nature
for a high binding affinity to specific biological targets and the ability to induce a biological
effect, such as activation or inhibition of a protein. Examples of NPs used as drugs include
the anticancer agent paclitaxel (Taxol), which is isolated from the bark of the Pacific yew tree
and targets microtubules [3], as well as the fungal metabolite cyclosporine which suppresses the
immune response after organ transplants [4].
A number of structurally diverse NPs have been identified capable of interfering with the
actin cytoskeleton. [5] Actin is involved in many cellular processes such as motility, division,
cytokinesis, and muscle contraction. [6] The reversible assembly of monomeric actin (G-actin) to
filamentous actin (F-actin) is controlled by a variety of actin-binding proteins such as profilin,
gelsolin, and DNase I. In cancer cells, the F-actin morphology is substantially transformed,
making actin a potential drug target against tumor cell growth and metastasis. [7–10] Moreover,
disruption of actin filaments has been shown to reduce intraocular pressure in monkeys, which
may be useful as treatment of glaucoma. [11] Actin-binding NPs can either stabilize actin
filaments (e.g. phalloidin, jasplakinolide) or depolymerize them (e.g. swinholide A, aplyronine
A), the latter either by actively disrupting the filaments or by monomer sequestration. [5]
Crystal structures show most actin-targeting NPs binding to the hydrophobic cleft at the so-
called barbed end of actin between subdomains 1 and 3. [5] As of today only one class of actin
inhibitors targeting the pointed end above the nucleotide binding site is known, the latrunculins,
which are macrolide toxins containing a unique thiazolidinone ring. They are produced by
sponges in the Red Sea as chemical defense against predators. [12, 13]
Since latrunculin as well as other actin-binding NPs are difficult to synthesize or extract
from natural sources such as marine sponges, there is a demand for novel chemical scaffolds for
the development of actin-targeting anticancer and antiglaucoma drugs. To address this need, we
report a high-throughput docking campaign targeting the latrunculin binding site of actin. A
library of fragments obtained by decomposing a collection of NPs is used in the virtual screening
since NP-derived fragments are expected to possess chemical properties facilitating the binding
to biological targets, but are less complex than the original molecules. The decomposition is
carried out according to a set of rules derived from organic synthesis, allowing a coupling of
promising fragments to synthetically accessible molecules at a later stage of the project.
Since consensus scoring has been shown to yield higher hit rates than the use of only a single
scoring function [14,15], the poses are ranked according to the median rank of different scoring
functions: the SEED [16, 17] total and electrostatic interaction energy, the CHARMm [18]
total interaction energy and van der Waals efficiency, the number of rotatable bonds, and
the ligand strain. Explicit solvent molecular dynamics (MD) simulations are performed to
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investigate the binding behavior of the hits found in the virtual screening campaign at an
atomistic level of detail. The unbinding times calculated by a single-exponential fit of the
cumulative distribution of unbinding events suggest a micromolar activity for most compounds.
[19] Ligands with a stable binding mode and high unbinding time in MD simulations are selected
for chemical synthesis and experimental determination of binding affinity. Furthermore, an
in silico optimization of a promising compound was carried out using the most populated
binding modes obtained by clustering of the MD trajectories. Addition of only two heavy atoms
improved both hydrophobic contacts and the stability of hydrogen bonds to the binding site
and lowered the number of spontaneous unbinding events, indicating a higher binding affinity
to actin for the optimized compound.
Materials and Methods
Protein preparation
The coordinates of G-actin in complex with latrunculin A [13] were downloaded from the PDB
database (PDB ID: 1ESV). The inhibitor and all water molecules were removed. As residues
1-5 are missing in the X-ray structure, the -COCH3 group was added to the N-terminal Thr6.
The C-terminus was considered negatively charged.
Due to the high flexibility of the DNase I binding loop (D-loop), the coordinates of its
residues are not present in the PDB file (residues 40-50). As in previously published MD studies
of G-actin, [20–23] initial D-loop coordinates were obtained from an actin crystal structure
with the D-loop residues resolved. Using SWISS-MODEL, [24] the PDB structure 3DAW was
selected as template for the two following reasons. First, the 1ESV coordinate set is an ATP-
bound actin structure, which is also the case for 3DAW. Second, in 3DAW the protein used for
co-crystallization (which is a domain of twinfilin) binds between the actin subdomains 1 and 3
which are located far away from the D-loop, and thus the presence of the twinfilin domain does
not directly influence the conformation of the D-loop. Similar to the procedure described in [21],
after fitting the crystal structure to the template using the Cα atoms present in both structures,
the missing coordinates of the D-loop were taken from the template and inserted into the 1ESV
structure. To relax elongated bonds after the coordinate transfer, an energy minimization of
100 steps of the steepest descent (SD) and 1000 steps of the adopted basis Newton-Raphson
algorithm was carried out using the program CHARMM [25, 26] and the CHARMM22 force
field [27]. During the minimization a distance-dependent dielectric function of  = 4r was used,
and all coordinates present in the X-ray structure were kept fixed. To reproduce neutral pH
conditions, the side chains of aspartates and glutamates were negatively charged, those of lysines
and arginines were positively charged, and histidines were considered neutral.
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Preparation of the library of natural product-derived fragments
A library of natural products was assembled by downloading the NP subsets of the August 2009
versions of the ZINC library [28], the Crystallography Open Database
(http://www.crystallography.net), the Human Metabolome Database (http://www.hmdb.ca),
MicroSource Discovery (http://www.msdiscovery.com), and the Traditional Chinese Medicine
Database (http://tcm.cmu.edu.tw). Compounds containing metals were removed, yielding a
total of about 140,000 molecules. Babel [29] was used to assign protonation states according to
a pH of 7.4, and partial charges were calculated with the MPEOE approach using Witnotp [30].
The compounds were decomposed into molecular fragments according to a set of rules derived
from chemical retrosynthesis (Supplementary Material, Fig. S1) similar to the RECAP [31] rules
using the programs ReCore [32] and CoLibri [33]. The main difference between the applied rules
and the RECAP rules is that not all specified bonds are cut at the same time, but all possible
fragment combinations are generated from the original molecules by a successive application of
the cleavage rules. This way interesting structural motifs of the natural products are preserved
in the resulting fragments. Only fragments with a molecular weight between 50-400 g/mol and
up to 10 rotatable bonds were kept.
CHARMm atom types [18] were assigned to the remaining 150,000 fragments with Witnotp,
and all fragments were subject to an energy minimization using the CHARMm force field and
the program CHARMM [25, 26]. A distance-dependent dielectric function of  = 4r was used
in the minimization.
High-throughput docking
The NP-derived library was docked with version 4.2 of AutoDock [34] using a rigid protein.
First, AutoGrid was employed to generate the atom-specific affinity map files. The spacing
between two adjacent grid points was 0.375 A˚, and the numbers of points in the x, y, and z
directions were 76, 62, and 58, respectively. Subsequently, the Lamarckian genetic algorithm of
AutoDock, a hybrid genetic algorithm with local search, was run 50 times with different initial
seeds to obtain multiple poses, on average 17 poses per compound. The maximum number of
energy evaluations was set to 2,750,000 and the maximum number of generations to 27,000.
The poses generated by AutoDock were energy-minimized in the rigid protein with CHARMM
using the CHARMm force field and a distance-dependent dielectric function of  = 4r.
Consensus scoring
Combining multiple scoring functions for rescoring a set of docked poses, an approach called
consensus scoring, has been shown to increase performance in hit rates compared to using only
a single scoring function. [14,15] The energy functions used for consensus scoring in this study
are:
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1) The SEED [16,17] protein-compound total interaction energy.
2) The SEED protein-compound electrostatic interaction energy.
3) The CHARMm [18] protein-compound total interaction energy.
4) The CHARMm protein-compound van der Waals interaction efficiency, i.e., the van der
Waals interaction energy divided by the number of heavy atoms.
5) The number of rotatable bonds of the ligand.
6) The conformational strain of the ligand in the docked conformation, defined as the differ-
ence in intra-ligand energy in the protein-bound and -unbound conformation.
The SEED interaction energies were calculated using the SEED energy evaluation mode. The
SEED scoring function includes electrostatic interactions as well as receptor and fragment
desolvations calculated by an efficient numerical implementation of the generalized Born ap-
proach. [16, 17]
Ranking the poses according to the number of rotatable bonds is a simple approximation to
incorporate the entropic penalty of the ligand upon binding. For ligands with many rotatable
bonds the entropic cost due to loss of rotational degrees of freedom upon binding is higher than
for more rigid ligands. Note that in this simple approximation, a linear chain with six rotatable
bonds has the same estimated penalty as benzene with six -OCH3 substituents, for example,
even though the latter will have a much lower entropic penalty than the former upon binding.
The ranks according to the number of rotatable bonds were assigned by giving all n compounds
with no rotatable bonds a rank of 1. To the m compounds with one rotatable bond, a rank of
n+ 1 was assigned, to those with two rotatable bonds a rank of n+m+ 1, and so forth.
The ligand strain was calculated by minimizing the ligand conformation obtained by docking
first within the rigid protein and again after deletion of the protein atoms, using a distance-
dependent dielectric function of (r)=4r in both cases, and calculating the difference between
the two intramolecular energies of the ligand. Ligands adopting a high-energy conformation are
less likely to have high binding affinities. Note that the strain is calculated with respect to the
nearest local minimum of the unbound conformation.
After an independent ranking by each energy function, the poses were ranked according to
the median rank since the median is less sensitive to outliers compared to the average. [35] The
poses were ranked by the median rank of functions 1-4, 1-5, and 1-6, since visual examination of
the 400 top-ranking molecules revealed no distinct difference in quality of the binding poses for
the three combinations of energy functions. Including the AMBER-based [36] AutoDock scoring
function did not yield a higher number of reasonable binding poses among the 400 top-ranking
compounds. The AMBER and CHARMm force field are based on similar principles, therefore
using both force fields is partially redundant. In the visual inspection special attention was paid
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to the number and geometry of hydrogen bonds to the key residues Tyr69, Asp157, Thr186,
and Arg210, which are also involved in hydrogen bonds in the actin/latrunculin complex, as
well as to van der Waals interactions to side chains of hydrophobic residues in the binding site
(e.g. Pro32 and Ile34). Ten compounds were selected according to the median rank of energy
functions 1-4, one compound according to 1-5, and four compounds according to 1-6, and their
binding behavior was studied in MD simulations.
MD simulations
For each ligand 10-20 independent MD runs were carried out with different initial velocities,
starting from the docked conformation obtained by AutoDock. Starting poses for derivatives of
the selected compounds (see Results section) were designed by changing the chemical structures
using Witnotp and minimizing the resulting molecules in the rigid protein using CHARMM and
the CHARMm force field. A distance-dependent dielectric function of  = 4r was used in the
minimization.
For promising compounds with a low number of unbinding events in the first 10 runs and
reasonable synthetic feasibility, additional runs were performed, explaining the different number
of runs for different compounds. The runs were stopped after 20 ns or before if the distance
between the ligand center of mass and the center of mass of the binding site (residues Gly15,
Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183, Thr186, Arg206, Glu207, and
Arg210) exceeded 20 A˚.
For the MD simulations the protein was immersed in an orthorhombic box of pre-equilibrated
water molecules. The size of the box was chosen to have a minimal distance of 13 A˚ between
the boundary and any atom of the protein. VMD [37] was used for setting up the simulation
system, while minimization, heating and production runs were performed with NAMD [38]
using the CHARMM22 force field and the TIP3P model of water. For the parameters of the
ligands the CGenFF force field [39] was used. Periodic boundary conditions were applied, and
the particle-mesh Ewald approach [40] was used for the long-range electrostatics. The van der
Waals interactions were truncated at a cutoff of 12 A˚ and a switch function was applied starting
at 10 A˚. The MD simulations were carried out at constant temperature (310 K) and constant
pressure (1 atm) with a time step of 2 fs using the SHAKE algorithm [41] to fix the length of
covalent bonds involving hydrogen atoms.
Clustering procedure
To determine the most populated binding modes of compound 42070 in the MD simulations, the
trajectories of all individual runs of the ligand were merged and then clustered using Witnotp.
First, the non-symmetric heavy atoms of the binding site residues were aligned. Subsequently,
the ligand poses were clustered using all non-symmetric heavy atoms of the ligand and a clus-
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tering cutoff of 2.5 A˚. The option “metric inplace rmsd” was chosen in Witnotp to also take
translation and not just different orientations and conformations of the ligand into account.
The most populated clusters were visualized for in silico optimization of the binding behavior
of compound 42070.
Results
The workflow implemented in the in silico screening campaign is depicted in Fig. 2.1. After
decomposing the library of about 140,000 natural products, fragments with a molecular weight
higher than 400 g/mol were discarded to allow a margin for later lead optimization which
generally results in an increased molecular weight. Moreover, fragments with a molecular weight
below 50 g/mol were considered too small and unspecific and were removed from the library as
well. Fragments with more than 10 torsional degrees of freedom were also discarded because
with an increasing number of rotatable bonds it becomes more difficult for the docking program
to find meaningful poses, since a much larger conformational space has to be sampled.
The decomposition according to a set of rules inferred from organic synthesis (Supplementary
Material, Fig. S1) produces building blocks which can be recombined to form synthetically
accessible structures. However, a large number of fragments has a molecular weight already
within the range of leadlike compounds (Fig. 2.2, top left). Due to their relatively high molecular
weight the fragments were considered to be whole molecules and a combination of fragments
was not performed at this stage of the project, but is interesting for later lead optimization.
Most molecules fulfill Lipinski’s rule of five [42], increasing their potential as candidates for
orally bioavailable drugs.
Compounds selected by flexible ligand docking and consensus scoring
After docking the NP-derived library and sorting the poses according to the median ranks
of the three combinations of scoring functions (see Materials and Methods section), the 400
top-ranking compounds for each combination were visually examined. Considering the quality
of the binding poses, synthetic accessibility, as well as chemical diversity, 15 compounds were
selected for MD simulations. The chemical structures of the compounds are shown in Fig. S2
and S3 (Supplementary Material). Despite their reactivity, molecules with an aldehyde group
were chosen as well since the aldehyde functionality can be replaced by a bioisostere in later
optimization steps. In addition to the molecules chosen from consensus scoring, commercially
available or synthetically easily accessible derivatives of the chosen compounds were identified
(compounds labeled 42070methoxy, 42070phe, 42070tyr, 102213enantio, 106499deriv1, and both
enantiomers of 106499deriv2). Derivatives of compound 42070 were designed to improve the
binding affinity of the original molecule (42070opt1, 42070opt1 deriv1, 42070opt1 deriv2, 42070opt2,
42070opt2 5ring, 42070opt3, 42070opt5), yielding a total of 29 molecules whose binding behavior to
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actin was investigated by MD simulations.
Only the combination of six scoring functions including the ligand strain produced a ranking
in which latrunculin is among the 400 top-ranking compounds. If it were included in the library,
latrunculin would have rank 375 in the consensus scoring of scoring functions 1-6, rank 1535
for functions 1-5, and 1231 for functions 1-4. Nevertheless, all three types of consensus scoring
were used for hit identification since visual examination showed no significant differences in the
quality of binding poses between the three sets of 400 NP-inspired top-ranking molecules.
As an example, the binding mode of compound 42070 predicted by AutoDock is shown
in Fig. 2.4. The aromatic ring is fixed deep in the binding site by a hydrogen bond between
the phenolic hydroxyl group and Asp157. According to the predicted binding mode Tyr69 is
involved in a hydrogen bond to the ether oxygen which is a rather weak acceptor. Arg210
and the carboxylate group of the ligand participate in a strong electrostatic interaction. The
isopropyl group of compound 42070 is located in the vicinity of the side chains of Pro32 and
Ile34, indicating the existence of hydrophobic contacts.
Examination of ligand binding behavior by MD simulations
To assess the stability of the binding modes predicted by docking and investigate the binding
behavior of the selected compounds, 10-20 independent MD simulations per compound were
carried out. The low values of the Cα root mean square deviation (RMSD) of actin from the
X-ray structure indicate that the overall structural stability of the protein is preserved in the
MD simulations (Fig. 2.3).
An overview of the performed MD runs is presented in Table 2.1. The compounds undergo
between zero and 14 spontaneous unbinding events, where an unbinding event is defined as a
separation of the ligand center of mass from the center of mass of the binding site larger than
10 A˚. Comparable numbers of unbinding events are obtained by applying a distance cutoff of 8 A˚
or 12 A˚. For instance, both a 8 A˚ and a 10 A˚ cutoff result in 14 dissociation events for compound
104690, while a 12 A˚ cutoff yields 13 events. For compound 109412 the corresponding values
are 8, 7, and 7 unbinding events for 8 A˚, 10 A˚ and 12 A˚. A criterion of 10 A˚ was chosen to be
consistent with a previously published study of ligand unbinding for the FK506 binding protein
(FKBP) by Huang and Caflisch. [19] Time series of the distances between the ligands and the
binding pocket (Supplementary Material, Fig. S4-S32) indicate that multiple binding modes
and dissociation pathways exist for most ligands, in agreement with the binding behavior of the
FKBP ligands observed in [19]. Compound 42070opt1, for example, dissociates quickly from the
binding site in run 16, remains stable for 20 ns in a number of runs such as run 13, and shows a
number of different binding modes in run 7, where it almost unbinds at about 10 ns, but then
moves partly back into the binding pocket for a couple of nanoseconds (Supplementary Material,
Fig. S8). Compound 104690, however, unbinds quickly in 14 out of 20 runs (Fig. S21), while e.g.
compound 105302 remains stable in all runs (Fig. S22). Even though compound 106230 does
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not unbind in run 10, the binding mode is not stable as indicated by the strong fluctuations
(Fig. S24). Only 10 runs were carried out of the spiro compound 34985 as it unbinds 9 out of 10
simulations. The disaccharide 37644 is prone to hydrolytic cleavage by metabolic enzymes and
therefore not considered for a probably time-consuming synthesis. Only 10 runs of compounds
106499deriv2 enantio1 and 106499deriv2 enantio2 were performed because in vitro assays did not
show a significant binding affinity (unpublished results).
Unbinding times were extracted for each ligand with at least 5 unbinding events by fit-
ting the cumulative distribution of unbinding events with a single exponential function f(t) =
exp(−t/τ fitMD) (Supplementary Material, Fig. S35). Ideally, τ
fit
MD should be correlated with the
experimentally measured binding affinity of the ligands, as observed in [19]. The unbinding
times are determined both by a leave-one-out and a block averaging procedure (see caption of
Table 2.1). Note, however, that polarization effects are neglected in the fixed-charge CHARMM
force field which has a stronger influence on compounds with a higher charge. Therefore, the
unbinding times should not be directly compared between ligands of different charge. The good
performance of compounds 105302 and 42783, which did not unbind in any of the MD runs,
could be associated with their high charge. The determined unbinding times of 7-76 ns sug-
gest an activity within the micromolar range, an estimation based on a linear fitting of the
unbinding times of six ligands of FKBP to their experimentally measured binding energies. [19]
The single-exponential behavior observed for the cumulative distributions of unbinding events
suggests that one predominant free energy barrier exists, the barrier of ligand unbinding, while
the barriers between subbasins of the bound state are much lower, as observed in [19]. The
subbasins of the bound state correspond to different binding modes.
The in vitro binding affinity and cytotoxicity of a number of compounds listed in Table 2.1
are currently being investigated in the Department of Organic Chemistry at the University of
Zu¨rich.
In silico optimization
To further investigate the binding behavior of promising compounds, the MD trajectories were
clustered according to different ligand binding modes (see Materials and Methods section) and
representatives of the most populated clusters were visualized. The three most populated clus-
ters of compound 42070 have almost equal statistical weights of 12%, 11%, and 10% for a
clustering cutoff of 2.5 A˚. For a cutoff of 2.0 A˚ the corresponding values are 10%, 9%, and 7%.
The binding mode of the second most populated cluster (cutoff of 2.5 A˚) is very similar to the
binding mode predicted by docking (Fig. 2.4, bottom right). While the position of the aromatic
ring in the most populated cluster is similar to the AutoDock pose, the aliphatic side chain has
rotated so that the carboxylate group is involved in hydrogen bonds to both Tyr69 and Arg206.
The probably weak hydrogen bond between Tyr69 and the ether group in the docked pose is
broken and replaced by a hydrogen bond to the nitrogen-bound hydrogen of the amide group.
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Based on the binding modes of the most populated clusters, hydrophobic contacts between
the apolar side chains of Pro32, Ile34, and Leu67 and compound 42070 can be reinforced by
introducing apolar groups close to the isopropyl moiety. Thus, compound 42070 was chosen for
in silico lead optimization. Moreover, compound 42070 has only one negative charge, not too
many unbinding events (6 out of 20 runs), as well as some MD runs with a nearly perfectly stable
binding mode (e.g. runs 2 and 10, see Fig. S6) indicating the existence of stable interactions
between the molecule and the binding pocket.
The optimization was focused on improving hydrophobic interactions. Generally the burial
of hydrophobic surface area upon ligand binding is the single parameter to correlate with binding
affinity, while the contribution of hydrogen bonds depends strongly on desolvation effects. [43]
Since the native ligand latrunculin has a large apolar surface area, strong hydrophobic contacts
to the actin binding site at the pointed end are likely to be of great importance for a high
binding affinity.
The phenolic hydroxyl group of compound 42070 is involved in hydrogen bonds in appr.
70% of the simulation time, formed almost exclusively to Asp157 (Fig. S6, top right and bottom
left). As a consequence, the phenyl ring is tightly bound deep in the binding site for most of
the simulation time. The aliphatic side chain of compound 42070 is more flexible. Its amide
and ether groups form hydrogen bonds in less than 30% of all snapshots. The carboxylate
group, however, participates in electrostatic interactions in about 70% of the simulation time,
predominantly to Arg210 and to a lesser extent to Arg62 and Arg206 (Fig. S6, bottom right).
Based on these observations and visual examination of the binding modes in the most pop-
ulated clusters, seven derivatives of compound 42070 were designed and their binding behavior
examined by MD simulations (compounds 42070opt1, 42070opt1 deriv1, 42070opt1 deriv2, 42070opt2,
42070opt2 5ring, 42070opt3, and 42070opt5). As some torsional degrees of freedom are fixed by the
ring structure, the entropic penalty upon binding is likely to be lower for derivatives 42070opt2
and 42070opt2 5ring compared to acyclic structures. In addition, the binding behavior of the
commercially available compound 42070methoxy, as well as that of compounds 42070phe and
42070tyr, was investigated by MD. The latter two molecules can easily be synthesized, and the
newly introduced phenylalanine- and tyrosine-derived moieties fit into the binding site after
minimization with CHARMM.
The unbinding times of the derivatives of compound 42070 are given in Table 2.1. The
most promising lead for actin inhibition is derivative 42070opt1. It has only three unbinding
events compared to six events of the parent compound. The time series of the distance between
42070opt1 and the binding site show a higher stability of the derivative compared to the parent
molecule (Supplementary Material, Fig. S8). The average occupancy of the hydrogen bond
between Asp157 and the phenolic hydroxyl group is increased from appr. 65% to 79% of the
simulation time, indicating the phenyl ring is more stable in the derivative (green columns in
Fig. S6). However, the most significant increase is in side chain stability. The carboxylate group
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forms an electrostatic interaction to Arg210 in 73% of all snapshots compared to 44% for the
original molecule 42070. The NH group of the amide, however, is no longer involved in hydrogen
bonds in the derivative due to the steric requirements of the newly introduced methyl group
at R1. Hydrophobic contacts between compound 42070opt1 are more stable in comparison to
compound 42070, as shown by more stable time series of the distance between the ligand and
hydrophobic residues (Supplementary Material, Fig. S33 and S34). The three most populated
clusters of compound 42070opt1 have statistical weights of 21%, 8%, and 7% for a clustering cutoff
of 2.5 A˚ compared to 12%, 11%, and 10% for compound 42070, indicating that the addition
of only two heavy atoms has increased the stability of the most frequently occurring binding
mode. The highly occupied hydrogen bond between the phenolic hydroxyl group and Asp157
is lost in the commercially available compound 42070methoxy due to the methylation of the OH
group, providing a reasonable explanation for the much lower unbinding time of this derivative
compared to the original compound 42070. The increased hydrogen bond occupancy of the
carboxylate group in 42070opt5 compared to 42070 is compensated by a decreased occupancy
of the amide group. The unbinding times of compound 42070opt5 and 42070 are almost equal,
indicating the presence of the methyl group at R1 is key to improving binding affinity.
Conclusions
A virtual screening campaign of a NP-derived library was carried out to discover novel leads
targeting actin. Several interesting structures were selected as candidate ligands after reranking
the poses by consensus scoring. Investigating the binding behavior using explicit water MD sim-
ulations revealed great differences in the stability of the binding modes. While some molecules
unbind after a few nanoseconds in many independent runs, others show a significant degree
of stability and are promising candidate ligands for lead development. The unbinding times
calculated by a single-exponential fit of the cumulative distribution of unbinding events suggest
a micromolar activity for most molecules. Addition of only two heavy atoms to compound
42070 improved the stability of the most populated binding mode significantly by decreasing
side chain flexibility due to stronger hydrophobic contacts and hydrogen bonds to the binding
site. The high stability of the binding mode of the optimized compound suggests this structure
has a high potential as lead candidate. As a next step, the binding affinities of the suggested
molecules will be determined experimentally by in vitro binding assays (work in progress).
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Tables and Figures
140,000 natural products
  1. Decomposition according
    to chemical synthesis
  2. Mw= 50 - 400g/mol, no.
    rotatable bonds   10
150,000 fragments
1. Docking
2. Consensus scoring: 
   3 combinations of 
   scoring functions
3x400 top-ranking compounds
Visual inspection
15 compounds
1. Additionally:
    search for
    purchasable
    derivatives
2. Additionally:
    optimization of 
    promising 
    compounds
32 compounds selected for MD
Figure 2.1: Schematic picture of the workflow implemented in the in silico screening campaign.
Docking of the 150,000 NP fragments was carried out by AutoDock using the 1ESV crystal
structure of G-actin as explained in the text.
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Figure 2.2: Normalized distributions of physicochemical properties of the NP-derived fragment
library used for virtual screening. The vertical black lines represent the thresholds defined by
Lipinski’s rule of five. [42]
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Figure 2.3: (Left) Structure of G-actin in complex with latrunculin A based on the 1ESV
crystal structure. Actin is conventionally divided into two major domains. Domain 1 consists
of subdomains 1 (shown in red) and 2 (orange), while domain 2 consists of subdomains 3 (light
blue) and 4 (dark blue). ATP (green) and latrunculin (gray) bind in a cleft between the two
domains. (Right) Time series of RMSD from the actin crystal structure for two runs of actin
in complex with compound 113367 (black and red line) and one run for the complex with
compound 42070opt5 (green line). All Cα atoms (except the D-loop) were used for alignment
and calculation of the RMSD. Similar RMSD time series are obtained for other ligands.
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Unbinding time Unbinding time
No. of No. of unbinding (leave-one-out)c (block average)d
Ligand runsa eventsb [ns] [ns] Charge
34985 10 9 7 ± 1 5, 7 0
37644 15 1 < 5 events < 8 events 0
42070 20 6 47 ± 2 < 8 events -1
42070methoxy 20 13 20 ± 1 14, 24 -1
42070opt1 20 3 < 5 events < 8 events -1
42070opt1 deriv1 10 1 < 5 events < 8 events -1
42070opt1 deriv2 10 4 < 5 events < 8 events -1
42070opt2 20 7 48 ± 2 < 8 events -1
42070opt2 5ring 10 1 < 5 events < 8 events -1
42070opt3 20 7 48 ± 2 < 8 events -1
42070opt5 20 6 51 ± 1 < 8 events -1
42070phe 10 4 < 5 events < 8 events -1
42070tyr 10 4 < 5 events < 8 events -1
42430 20 5 76 ± 5 < 8 events -1
42783 20 0 < 8 events < 8 events -2
102213 16 7 36 ± 1 < 8 events -1
102213enantio 20 7 46 ± 1 < 8 events -1
104690 20 14 23 ± 1 18, 25 0
105302 15 0 < 5 events < 8 events -2
105339 20 12 25 ± 1 23, 24 0
106230 20 6 66 ± 4 < 8 events 0
106499 15 3 < 5 events < 8 events -1
106499deriv1 20 9 31 ± 1 21,38 -1
106499deriv2 enantio1 10 1 < 5 events < 8 events -1
106499deriv2 enantio2 10 0 < 5 events < 8 events -1
106540 20 6 56 ± 3 < 8 events 0
108360 20 9 42 ± 1 28,49 0
109412 20 7 46 ± 2 < 8 events 0
113367 20 6 76 ± 4 < 8 events 0
Table 2.1: aMultiple runs were started using different seeds to generate a random distribution
of the initial velocities. bAn unbinding event is defined as a separation of the ligand center of
mass from the center of mass of the binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59,
Tyr69, Asp157, Gly182, Arg183, Thr186, Arg206, Glu207, and Arg210) larger than 10 A˚.
cLeave-one-out unbinding times were calculated for molecules with at least five dissociation
events by performing x single exponential fits, where x is the number of unbinding events. The
average values of unbinding time and rms error are reported in the table. dBlock averaging was
performed for molecules with at least eight unbinding events by partitioning the 10-20 individual
runs of one compound into two blocks of equal size. The arithmetic mean of the unbinding time
calculated for each of the two blocks is given in the table.
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Figure 2.4: (Top) Binding mode of compound 42070 predicted by docking. (Bottom) Binding
mode of compound 42070 according to the most populated (left) and second most populated
(right) cluster in MD simulations.
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Figure 2.5: (Top left) Chemical structure of compounds 42070, 42070opt1, 42070opt5, and
42070methoxy. (Top right) Occupancy of hydrogen bond donors and acceptors, i.e., the per-
centage of simulation time where a hydrogen bond is formed, for compounds 42070, 42070opt1,
42070opt5, and 42070methoxy averaged over all runs of each compound. The carboxylate group is
labeled as COO−, the amide nitrogen and oxygen as NH and CO, respectively, the ether group
as ROR’, and the phenolic hydroxyl or methoxy group as PheOR3. (Bottom left) Average oc-
cupancy of different residues involved in a hydrogen bond to the phenolic hydroxyl group of the
ligands. (Bottom right) Average occupancy of different residues involved in a hydrogen bond
to the carboxylate group of the ligands.
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Figure S4: Time series of distance between centers of mass of compound 34985 and the actin
binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of
10 A˚, while the green line is the distance averaged over the first 10 snapshots and was drawn
for visual help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S5: Time series of distance between centers of mass of compound 37644 and the actin
binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of
10 A˚, while the green line is the distance averaged over the first 10 snapshots and was drawn
for visual help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S6: Time series of distance between centers of mass of compound 42070 and the actin
binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of
10 A˚, while the green line is the distance averaged over the first 10 snapshots and was drawn
for visual help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S7: Time series of distance between centers of mass of compound 42070methoxy and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S8: Time series of distance between centers of mass of compound 42070opt1 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S9: Time series of distance between centers of mass of compound 42070opt1 deriv1 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S10: Time series of distance between centers of mass of compound 42070opt1 deriv2 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S11: Time series of distance between centers of mass of compound 42070opt2 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S12: Time series of distance between centers of mass of compound 42070opt2 5ring and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S13: Time series of distance between centers of mass of compound 42070opt3 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S14: Time series of distance between centers of mass of compound 42070opt5 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S15: Time series of distance between centers of mass of compound 42070phe and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S16: Time series of distance between centers of mass of compound 42070tyr and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S17: Time series of distance between centers of mass of compound 42430 and the actin
binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of
10 A˚, while the green line is the distance averaged over the first 10 snapshots and was drawn
for visual help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S18: Time series of distance between centers of mass of compound 42783 and the actin
binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of
10 A˚, while the green line is the distance averaged over the first 10 snapshots and was drawn
for visual help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S19: Time series of distance between centers of mass of compound 102213 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S20: Time series of distance between centers of mass of compound 102213enantio and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S21: Time series of distance between centers of mass of compound 104690 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S22: Time series of distance between centers of mass of compound 105302 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S23: Time series of distance between centers of mass of compound 105339 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S24: Time series of distance between centers of mass of compound 106230 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S25: Time series of distance between centers of mass of compound 106499 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S26: Time series of distance between centers of mass of compound 106499deriv1 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S27: Time series of distance between centers of mass of compound 106499deriv2 enantio1
and the actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182,
Arg183, Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion
of 10 A˚, while the green line is the distance averaged over the first 10 snapshots and was drawn
for visual help.
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Figure S28: Time series of distance between centers of mass of compound 106499deriv2 enantio2
and the actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182,
Arg183, Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion
of 10 A˚, while the green line is the distance averaged over the first 10 snapshots and was drawn
for visual help.
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Figure S29: Time series of distance between centers of mass of compound 106540 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S30: Time series of distance between centers of mass of compound 108360 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S31: Time series of distance between centers of mass of compound 109412 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S32: Time series of distance between centers of mass of compound 113367 and the
actin binding site (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183,
Thr186, Arg206, Glu207, and Arg210). The blue line illustrates the unbinding criterion of 10 A˚,
while the green line is the distance averaged over the first 10 snapshots and was drawn for visual
help. “Compound” is abbreviated as “cpd” in the legends.
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Figure S33: Time series of distance between isopropyl group of compound 42070 and hydropho-
bic residues (Pro32 (red), Ile34 (green), and Leu67 (blue)) in binding site
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Figure S34: Time series of distance between isobutyl group of compound 42070opt1 and hy-
drophobic residues (Pro32 (red), Ile34 (green), and Leu67 (blue)) in binding site.
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Figure S35: Single exponential kinetics of unbinding for ligands with at least five unbinding
events. The plots show the cumulative distribution f(t) of the unbinding times observed in
the 10-20 runs. The unbinding times and standard deviation of the fits (σfit) are given in the
legends.
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Chapter 3
De Novo design of G-actin inhibitors
Introduction
Computer-aided drug design is an established technology supporting experimental drug dis-
covery techniques such as high-throughput screening in the search for novel pharmaceutically
active agents. The most commonly used computational approach to drug discovery is virtual
screening, where large libraries of existing compounds are docked into a protein target and their
binding affinities estimated by a scoring function. An alternative approach to computer-aided
drug discovery is de novo design, in which potential ligands are constructed “from scratch”,
allowing the design of truly novel chemical structures for drug development. [1, 2] Since its in-
troduction about 20 years ago [1, 3], several programs for de novo design have been published
such as GANDI [4], FlexNovo [5], MEGA [6], AutoGrow [7], and SQUIRRELnovo [8]. Both
receptor-based and ligand-based scoring functions are commonly employed, where the latter is
based on a similarity measure to a compound known to bind to the target of interest. The
simultaneous optimization of more than one scoring function is referred to as multiobjective
optimization. In GANDI the individual scores of a force field energy term and the 2D or 3D
similarity to a known inhibitor are combined either by a weighted-sum [9] or a Pareto-based [10]
scoring approach.
The main advantage of de novo design over virtual screening is that a much larger part
of chemical space can be sampled. However, due to the vastness of chemical space, which has
been estimated to comprise appr. 1060-10100 druglike molecules, it is not feasible to evaluate all
theoretically possible compounds. [1] One of the main difficulties encountered in de novo design
is the generation of synthetically accessible molecules. This issues has been addressed by using
building blocks obtained by cleavage of existing compounds [11,12] and by applying connection
rules derived from organic synthesis, such as the RECAP rules [13], facilitating a combination
of building blocks by standard organic reactions.
Actin is a major constituent of the cytoskeleton and plays a crucial role in various cellular
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processes such as cell motility, adhesion, cytokinesis, and division. [14] Malignant modifications
of the actin cytoskeleton are observed in tumor cells, making actin a potential drug target against
cancer. [15–18] Additionally, actin-binding compounds are promising leads for the treatment of
glaucoma by disrupting the actin cytoskeleton in the trabecular meshwork, a type of tissue
in the eye, thereby increasing aqueous humour outflow and alleviating pressure on the optic
nerve. [19] As of today the only known actin inhibitors binding to the so-called pointed end
above the nucleotide binding site belong to the latrunculin family, a class of macrolide toxins
produced by sponges in the Red Sea to fight predators. [20,21] Due to the difficulties associated
with the extraction from natural sources and the synthesis of latrunculins as well as other actin-
binding natural products, there is a demand for novel chemical scaffolds for the development of
actin-targeting anticancer and antiglaucoma drugs.
This study aims at identifying novel actin inhibitors targeting the same binding cleft as
latrunculins by de novo design with GANDI. The crystal structure of the actin/latrunculin
complex [21] shows the thiazolidinone ring of latrunculin buried in a subpocket deep in the
binding site. As this unique moiety is shared by all active representatives of the latrunculin
family, it is likely to be a key factor for a high binding affinity and selectivity. To identify potent
actin inhibitors, the thiazolidinone ring is used as an anchor fragment for growing fragments
obtained by decomposition and 2D structural clustering of a library of leadlike compounds. Dif-
ferent scoring schemes implemented in GANDI are evaluated to determine an optimal scoring
method for the generation of novel actin-binding molecules. A number of interesting molecules
presenting similar hydrogen bond patterns and more favorable van der Waals interaction ef-
ficiencies relative to latrunculin were obtained using GANDI, suggesting these molecules are
promising candidates for chemical synthesis and measurement of in vitro binding affinity.
Materials and Methods
Protein preparation
The coordinates of actin in complex with latrunculin A [21] were downloaded from the PDB
database (PDB ID: 1ESV). The inhibitor and all water molecules were removed. As residues 1-5
are missing in the X-ray structure, the -COCH3 group was added to the N-terminal Thr6. The
C-terminus was considered negatively charged. Hydrogens were added according to a pH of 7.4
using Babel [22], and CHARMm atom types [23] were assigned with Witnotp [24]. Hydrogen
positions were subject to an energy minimization of 100 steps of the steepest descent (SD)
and 1000 steps of the adopted basis Newton-Raphson algorithm using the program CHARMM
[25, 26] and the CHARMm force field [23]. During the minimization a distance-dependent
dielectric function of (r) = 4r was used, and all coordinates present in the X-ray structure
were kept fixed.
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Preparation of latrunculin as target for structural similarity
The coordinates of latrunculin were taken from the PDB structure 1ESV. Hydrogens were added
according to a pH of 7.4 using Babel, and CHARMm atom types were assigned with Witnotp.
Hydrogen positions were energy-minimized as described above for the protein.
Preparation of thiazolidinone ring as anchor fragment
The thiazolidinone ring was prepared by taking the coordinates from the crystallographic la-
trunculin in the PDB structure 1ESV. Subsequently, the structure was prepared as described
before for latrunculin. To allow for a degree of conformational flexibility and increase the
chances that GANDI finds solutions, the thiazolidinone ring was docked into the binding site
using SEED [27, 27]. Poses docked into the same subpocket and with a similar orientation as
the thiazolidinone ring in the crystal structure were selected as additional starting points for
GANDI, yielding a total of six different poses.
Preparation and docking of fragment library
The leadlike subset (4.5 million compounds) of the April 2010 version of the ZINC database [28]
was downloaded and decomposed into fragments by DAIM [29]. The fragments were clustered
according to 2D structural similarity using DAIM fingerprints and a Tanimoto threshold of 0.98.
A small diversity set of building blocks is preferable to a large library due to a strong increase
in computation time by combinatorial explosion. The 16500 cluster representatives obtained
by DAIM were subject to a CHARMM minimization of 100 steps of the steepest descent (SD)
and 5000 steps of the adopted basis Newton-Raphson algorithm, using a distance-dependent
dielectric function of (r) = 4r and the CHARMm force field. Subsequently, the fragments
were docked into the binding site using SEED, keeping only poses with a SEED energy more
favorable than 0 kcal/mol.
De novo design with GANDI
Version 2.0 of GANDI [4] (Genetic Algorithm-Based de Novo Design of Inhibitors) was used to
join the fragments previously docked by SEED. GANDI employs a parallel genetic algorithm
in which a gene value corresponds to a single docked fragment position read in. Individuals of
both the parent and the children population compete for survival. In this study, the fragments
were successively grown to the thiazolidinone anchor fragment. Four islands, 100 individuals
per island, and 1000 iteration steps were used, and each run was repeated three times with
different random seeds. Between 100-300 molecules were generated in a single run.
The total score is minimized until the maximum number of iterations is reached. Two dif-
ferent scoring schemes are available. The weighted-sum approach employs a linear combination
of scoring function terms:
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Stotal = wffEff − w3DSim3D − wPH4SimPH4 (3.1)
where Stotal is the total score, Eff the force field energy, Sim3D the 3D similarity to a known
ligand, and SimPH4 the pharmacophore score. The weights for the scoring function terms are
wff, w3D, and wPH4, respectively. The force field energy consists of inter- and intramolecular
van der Waals and electrostatic terms. [4]
The 2D similarity term implemented in GANDI was not considered because using the knowl-
edge of the binding mode of latrunculin was preferred to a ligand-based design. For the phar-
macophore scoring term, the presence of a hydrogen bond to residues Tyr69 and Arg210 was
evaluated (see Results section), using a distance criterion of 2.8 A˚ between hydrogen and ac-
ceptor atoms. As a basis of comparison, the longest hydrogen bond distance in latrunculin is
2.6 A˚ between the oxygen atom of latrunculin’s hydroxyl group and the closest hydrogen of the
guanidinium group of Arg210. A slightly higher distance criterion compared to the longest bond
in the actin/latrunculin complex was chosen to allow for some side chain flexibility, considering
the usage of a rigid protein in GANDI.
In the Pareto-based scoring an individual A dominates over another individual B if the
scores of all scoring functions of A are equal or lower (at least one) than the corresponding
scores of B. A Pareto-based scoring does not require the tuning of any scoring function weights.
Table 3.1 gives an overview of the different setups used in this study.
setup scoring PH4 as scoring wff w3D wPH4 no. of fragments linker set
d Presence of OH
approacha term or filterb to linkc group at anchore
1 ws sc 0.02 1 1 2 small No
2 ws f 0.02 1 - 2 small No
3 p sc - - - 2 small No
4 p f - - - 2 small No
5 ws f 1 1 - 2 small No
6 ws f 0.01 1 - 2 small No
7 ws f 1 1 - 2 large No
8 ws f 1 1 - 3 large No
9 ws f 1 1 - 2 large Yes
Table 3.1: Overview of used GANDI setups.
aThe weighted-sum approach is labeled “ws”, Pareto-based scoring “p”.
bThe pharmacophore term (abbreviated as “PH4”) is either used in the scoring function (“sc”)
or as a filter criterion (“f”) after scoring.
c In all runs, one fragment is the thiazolidinone anchor fragment to which either two fragments
(in setup 8) or one fragment (in the remaining setups) are grown.
d The two linker sets are explained in the text.
eIn setup 9, the coordinates of the hydroxyl group of latrunculin are included in the anchor
fragment.
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Two different sets of linkers were used. The first set is the linker library from the GANDI
testcase, which consists of small molecules like ethanol, acetamide, acetate etc. This linker
set is used to produce compounds with a low molecular weight, and will be referred to as the
“small” linker library. As a second set of linkers the fragment library was filtered for fragments
with a molecular weight below 150 g/mol, yielding about 2100 molecules. This linker set will be
referred to as the “large” linker library to distinguish it from the small linker set. All heavy atom
- hydrogen atom vectors in fragments and linkers were used as connection vectors. In setups
where the pharmacophore term is not used in the scoring function, but as a filter criterion after
scoring (setups 2 and 4-9), the presence of a hydrogen bond to either Tyr69 or Arg210 was set
as mandatory.
All fragments of the docked fragment library were used in the different setups, with the
exception of setup 7 (only fragments with a molecular weight equal to or above 200 g/mol) and
8 (only fragments with a molecular weight below 200 g/mol) to obtain more reasonably sized
compounds. The volume explored by GANDI was restricted to that within 2 A˚ of latrunculin
in its bound conformation.
The number of GANDI-generated molecules forming hydrogen bonds to the receptor was
measured with CHARMM using a distance criterion of 2.8 A˚ between hydrogen and acceptor
atoms. The CHARMm protein-compound total interaction energy and protein-compound van
der Waals interaction efficiency, i.e., the energy divided by the number of heavy atoms, were
calculated after minimizing the compounds inside the rigid protein using 100 steps of the steepest
descent (SD) and 5000 steps of the adopted basis Newton-Raphson algorithm in CHARMM. A
distance-dependent dielectric function of (r)=4r and default nonbonding cutoffs were used in
the minimization.
Results
In the actin/latrunculin complex, latrunculin is involved in hydrogen bonds to Tyr69, Arg210,
Asp157, and Thr186, where the latter two residues interact with the thiazolidinone moiety
used as anchor fragment in GANDI (Fig. 3.1). The two residues Tyr69 and Arg210, which do
not interact with the anchor fragment, will be referred to as “key” residues in the following
sections. Their participation in strong hydrogen bonds is likely to be crucial for a high binding
affinity. The guanidinium group of Arg210 can function as a strong donor, and Tyr69 is placed
relatively deep in the binding site, allowing it to participate in strong hydrogen bonds due to
lower dielectric shielding. A desolvation of Tyr69 upon ligand binding without forming a new
hydrogen bond is likely to be energetically unfavorable.
To illustrate the minimization of the total score in a GANDI run, the evolution of individual
scoring function terms and the total score is shown for two individuals of setup 2 as an example
(Fig. 3.2). The total score (Fig. 3.2, top left) decreases monotonically over the 1000 performed
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iterations. For iteration steps where the total score remains constant relative to the previous
step, no better solution was found by the program and the currently selected linkers and docked
fragments remain the same. No new molecules are introduced into the population until indi-
viduals with a lower total score surviving the selection are found. Both the force field energy
and the 3D similarity (Fig. 3.2, top right and bottom) can either decrease or increase because
it is the weighted-sum of these terms which is optimized in the GANDI run. An increase in
one of the two terms is always accompanied by a decrease in the other, resulting in an overall
reduction of the total score. The evolution of the force field energy and the 3D similarity is
substantially different for the two individuals. Since a different set of docked poses was assigned
to the individuals at the start of the run, the optimization proceeds differently, i.e., different
linkers and poses survive the selection after each iteration step, resulting in the generation of
two different molecules.
Selection of optimal scoring method
Different scoring schemes implemented in GANDI were tested to determine an optimal scoring
method for the generation of candidate ligands targeting actin. The quality of the binding
modes generated by setups 1-4 (see Materials and Methods section) was evaluated according to
the presence of hydrogen bonds to the key residues in the actin binding site and by visual exam-
ination. Both the weighted-sum and Pareto-based approach including a pharmacophore term in
the scoring (setups 1 and 3) produce only around 20-25% of molecules with hydrogen bonds to
Tyr69 or Arg210 (Fig. 3.3). The percentage of compounds with hydrogen bond interactions to
Arg210 and especially to Tyr69 is significantly increased by using the pharmacophore function
not in the scoring, but as a filter criterion (setups 2 and 4). This observation is plausible: When
a pharmacophore term is incorporated in the scoring, its influence on the total score is lower
than when it is used as an independent filter term alter scoring, due to the presence of the force
field and 3D similarity terms. The percentage of compounds involved in hydrogen bonds to
both Tyr69 and Arg210 is 4% for setup 1, 14% for setup 2, 5% for setup 3, and 18% for setup 4.
Using the presence of both hydrogen bonds as a scoring function term or as a filter is a too strict
criterion and leads to GANDI not finding many solutions. Since visual examination revealed
that setup 2 results in the highest number of compounds with a reasonable filling of the binding
site (e.g. by forming hydrophobic contacts to apolar side chains of Pro32 and Ile34), setup 2,
i.e., a weighted-sum scoring with pharmacophore constraints as filter criterion, was selected as
scoring method. Employing the chosen scoring scheme, further GANDI runs were performed
with two different linker libraries and different weights for the scoring function terms to obtain
a diverse set of compounds (setups 2 and 5-9).
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Physicochemical properties of generated molecules
Fig. 3.4 shows the physicochemical properties of the compounds obtained by setups 2 and 5-9.
Most compounds generated with a small linker library (Fig. 3.4, left panels) as well as those
from setups 7 and 9 (Fig. 3.4, magenta and black lines in right panels) fulfill Lipinski’s rule
of five. [30] Growing two fragments with large linkers to the thiazolidinone moiety without the
hydroxyl group (setup 7) leads to compounds which are on average 50 g/mol heavier than those
obtained from setup 9. The hydroxyl group fills up space in the binding pocket, reducing the
possibilities of placing big fragments. Only the combination of three fragments results in a
high number of molecules with a too high molecular weight according to Lipinski’s rules of five
(setup 8, cyan line in Fig. 3.4). Appr. one third of the generated compounds have too many
rotatable bonds as well (Fig. 3.4, (b)), which is not observed for the other GANDI setups. Due
to their large size and high number of rotatable bonds and acceptors, some molecules obtained
from setup 8 might not be appropriate for lead optimization into an orally bioavailable drug.
More importantly, visual examination revealed that some of these molecules do not fill the space
of the binding site as perfectly as the smaller molecules generated by combining two fragments.
Since GANDI is not capable of forming ring systems, the generated molecules are linear. When
connecting three fragments, the third fragment is placed at the “edge” of the binding site,
preventing the formation of interactions.
Most compounds created by all GANDI setups conform to the Lipinski rules regarding clogP
and the number of hydrogen bond donors and acceptors, with the exception of setup 8 with a
significant amount of molecules with too many acceptors.
Even though it is informative to calculate the physicochemical properties of the created
molecules, Lipinski’s rule of five should not be used as a strict cutoff for the choice of candidate
ligands. There are a number of drugs on the market which do not comply with the Lipinski
rules, such as the immunosuppressant cyclosporine with a molecular weight of 1203 g/mol or
the tyrosine kinase inhibitor nilotinib with a molecular weight of 530 g/mol for the treatment
of chronic myelogenous leukemia, which are still commonly used therapeutic agents.
Evaluation of binding poses
To assess the quality of the binding poses generated by GANDI, the poses were evaluated
according to the presence of hydrogen bond interactions to key residues. Additionally, the
CHARMm total interaction energy and the CHARMm van der Waals interaction efficiency
were computed after an energy minimization of the compounds within the protein to obtain a
more reliable estimation of interaction energies. In contrast, the GANDI force field energy is
calculated without a prior minimization. As shown by the set of compounds generated using
the small linker library, different weights for the force field and 3D similarity term in the scoring
function do not lead to significant differences in the number of compounds forming hydrogen
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bonds to key residues (Fig. 3.5, left panel). The small increase in number of compounds with
interactions to Tyr69 using a low weight for the force field term (setup 6) is compensated by
a decrease of interactions to Arg210. The number of molecules with hydrogen bonds to both
key residues is around 10% for the three setups. Using the large linker library produces appr.
10% less molecules with interactions to Tyr69 (Fig. 3.5, right panel). Smaller linkers facilitate
the design of compounds with a better fit within the binding site capable of interacting with
the relatively buried Tyr69. In comparison to setup 7, the combination of three fragments
in setup 8 produces a higher number of molecules interacting with Arg210 on account of the
higher number of hydrogen bond acceptors in the created compounds (see previous section).
Setup 9 results in the by far highest number of molecules with hydrogen bonds to both residues.
The percentage of compounds bound to Arg210 is 100% for this setup due to the presence
of latrunculin’s hydroxyl group in the anchor fragment. The choice of linker library, number
of fragments to connect, and chemical structure of the fragment used as anchor has a greater
influence on the hydrogen bond forming properties of the resulting compounds than the weights
of the scoring function terms.
Almost all generated compounds have a CHARMm total interaction energy significantly
less favorable than latrunculin (Fig 3.6, (a)), which is not surprising given the low micromolar
binding affinity of this natural product. A relatively high number of molecules with a lower
interaction energy than latrunculin is only found for setup 8. This result is to be expected
as the CHARMm total interaction energy is highly size-dependent, mostly due to the van der
Waals contribution, and most molecules produced by setup 8 are heavier than latrunculin which
has a molecular weight of 422 g/mol. To address the issue of size-dependency, the CHARMm
van der Waals interaction efficiency was computed to evaluate the strength of van der Waals
interactions. Each of the run setups generated a small number of compounds with more favorable
van der Waals interaction efficiencies than latrunculin (Fig. 3.6, (b)). For the large linker library,
setup 9 achieves the most favorable and setup 8 the most unfavorable CHARMm van der Waals
efficiencies, which is closely related to the different distributions of molecular weights.
The most promising compounds satisfy both criteria described above, i.e., hydrogen bonds
to key residues and a favorable CHARMm van der Waals interaction efficiency. The number
of compounds with interactions to both Tyr69 and Arg210 and a CHARMm van der Waals
efficiency more favorable than -1.70 kcal/mol (latrunculin: -1.75 kcal/mol) are 3.0% (setup 2),
2.8% (setup 5), 3.0% (setup 6), 0.3% (setup 7), 0.3% (setup 8), and 12.1% (setup 9). The
chemical structures of two molecules of setup 2 and one molecule of setup 9 are shown in Fig. 3.7
as an example. Setup 9 results in the highest number of compounds fulfilling both criteria,
caused mainly by the hydroxyl group at thiazolidinone ring which substantially increases the
number of hydrogen bonds to both key residues. The higher number of compounds satisfying
both criteria for GANDI setups 2, 5, and 6 compared to 7 and 8 results mainly from more
favorable CHARMm van der Waals efficiencies caused by lower molecular weights of the created
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compounds.
Conclusion
In this study the de novo design software GANDI was used to design novel actin inhibitors.
Based on both the ability to form specific hydrogen bonds and a reasonable fit within the
binding site, the weighted-sum approach was found to produce the highest quality of binding
poses, and was therefore chosen as scoring scheme. No significant differences in the quality of
binding modes were observed by adjusting the weights of the force field and 3D similarity term
in the scoring. Even though notable differences in both hydrogen bond forming properties and
CHARMm interaction energies were obtained for compounds generated using different scoring
function terms and linker sets, a close visual examination revealed reasonable binding poses for
all six run setups. While setups 2, 5, 6, and 7 result in molecules which fit well into the binding
site, the number of compounds involved in both key hydrogen bonds is highest for setup 9 due
to the presence of latrunculin’s OH group. Visual examination revealed a number of interesting
structures for setup 8 as well which combines three instead of two fragments, though several
compounds do not fit perfectly into the binding site. The most promising candidate ligands were
obtained by selecting molecules with a favorable CHARMm van der Waals efficiency interacting
with both key residues, combined with a visual examination of the binding poses. Applying
this procedure, interesting novel structures from six GANDI setups are identified for chemical
synthesis and measurement of in vitro binding affinity to actin. In addition to the fragments
obtained from the ZINC library of commercially available compounds, we are currently docking
a library of natural product-derived fragments for use in GANDI. A natural product-inspired
fragment library is expected to be enriched in structural motifs favorable for binding to proteins,
and molecules constructed from these fragments are expected to be interesting candidate ligands
for the design of actin inhibitors.
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Figure 3.1: Two-dimensional scheme of latrunculin and G-actin residues involved in hydrogen
bonds according to the 1ESV crystal structure. The thiazolidinone moiety used as anchor
fragment in GANDI forms hydrogen bonds to Asp157 and Thr186. The hydrogen bond to
Glu214 is water-bridged and was therefore not considered in this study.
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Figure 3.2: Evolution of scoring function terms for two individuals generated by GANDI setup 2
(black: first individual in island 1 of run 1, blue: first individual in island 4 of run 1). (Top
left) Evolution of total score. (Top right) Evolution of force field energy. (Bottom) Evolution
of 3D similarity to latrunculin.
84
 0
 0.1
 0.2
 0.3
 0.4
 0.5
 0.6
 0.7
 0.8
 0.9
 1
 1.1
Tyr69 Arg210
Fr
eq
ue
nc
y
Residue
weighted sum, PH4 in scoring
weighted sum, PH4 filter
pareto, PH4 in scoring
pareto, PH4filter
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Figure 3.4: Physicochemical properties of compounds generated using GANDI setups 2, 5, and
6 (left) and 7-9 (right). (a) Distribution of molecular weights. (b) Distribution of number
of rotatable bonds. (c) Distribution of clogP. (d) Distribution of number of hydrogen bond
donors. (e) Distribution of number of hydrogen acceptors. The vertical black lines represent
the thresholds defined by Lipinski’s rule of five. [30] For comparison, the values for latrunculin
are represented by black arrows.
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Figure 3.5: Percentage of generated molecules involved in hydrogen bonds to key residues Tyr69,
Arg210, or both, for GANDI setups 2, 5, and 6 (left) and 7-9 (right).
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Figure 3.6: Distribution of CHARMm protein-compound interaction energies for compounds
generated using GANDI setups 2, 5, and 6 (left) and 7-9 (right). The black arrow shows the
corresponding value for latrunculin. (a) CHARMm protein-compound total interaction energies.
(b) CHARMm protein-compound van der Waals interaction efficiencies.
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Inhibition of interdomain motion in G-actin by
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INTRODUCTION
Actin plays an important role in various cellular proc-
esses such as cell motility, cell division, muscle contrac-
tion, and cytokinesis.1 It is the most abundant protein in
many eukaryotic cells and highly conserved among differ-
ent organisms. The globular monomeric form, called G-
actin, can reversibly assemble to form filamentous actin
(F-actin) via a process controlled by a large number of
actin-binding proteins. F-actin constitutes an integral
part of the cytoskeleton. In tumor cells, the actin fila-
ment morphology is substantially altered which, together
with its role in cell division, suggests that actin is a
potential drug target.2–5
The first crystal structure of G-actin was published in
1990,6 and today there are more than 80 actin crystal
structures available in the Protein Data Bank7 (PDB).
Actin polymerization is inhibited by a number of natural
products including latrunculins, a class of macrolide tox-
ins produced by sponges in the Red Sea, including the
genus Latrunculia, whence the name is derived.8 The
crystal structure of the G-actin/latrunculin A complex9
shows the macrolide binding above the nucleotide bind-
ing site between the two major domains of G-actin
(Fig.F1 1, top left), with its unique 2-thiazolidinone moiety
buried deep in the cleft (Fig.F2 2, top). Latrunculins have
antiproliferative, antiangiogenic, antimetastatic, and anti-
microbial effects.10–14 In addition, they reduce intraocu-
lar pressure in monkeys, such that they may be useful as
treatment agents for glaucoma.15 Aside from naturally
occurring latrunculins, several synthetic analogs are like-
wise capable of disrupting actin filaments.14,16–18
Recent X-ray fiber diffraction data show the main con-
formational change in the G- to F-actin transition to be
a relative rotation of the two major domains by about
208, resulting in a flat actin monomer in the filament.19
The structural flattening has been confirmed by cryo-
EM20,21 and a recently published F-actin model by
Holmes and coworkers.22
Several computational studies have investigated the
structural features and plasticity of G- and F-actin.
Molecular dynamics (MD) simulations have shed light
on the influence of the bound nucleotide on actin
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conformation.23–26 The conformation of the DNase I
binding loop (D-loop) is still controversially discussed.
Although Zheng et al. observed an unfolded D-loop in
the ATP-bound and a folded loop in the ADP-bound
state,24 a nucleotide-dependence of the D-loop confor-
mation could not be confirmed by Dalhaimer et al.25 or
Splettstoesser et al.26 In a recent metadynamics simula-
tion study, it was found that the folded and unfolded
states of the D-loop are similarly stable in ADP–actin.23
Moreover, MD simulations indicate that the predominant
form of G-actin is the closed and twisted conformation,
independent of the nature of the bound nucleotide.25
The open conformation of actin, observed only in
complex with profilin, was found to be unstable upon
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ID: nagarajulum Date: 20/4/12 Time: 21:01 Path: N:/3b2/PROT/VOL00000/120077/APPFile/JW-PROT120077
Figure 1
Structure and plasticity of G-actin. (Top, left) Structure of G-actin in complex with latrunculin A based on the 1ESV crystal structure. Actin is
conventionally divided into two major domains. Domain 1 consists of Subdomains 1 (residues 1–32, 70–144, and 338–375, shown in red) and 2
(33–69, orange), while Domain 2 consists of Subdomains 3 (145–180 and 270–337, light blue) and 4 (181–269, dark blue). ATP (green) and
latrunculin (gray) bind in a cleft between the two domains. (Top, right) RMSFs of Ca atoms in A˚ as a function of residue number for ATP–actin
(black) and latr.–ATP–actin (red). The RMSF values are average values over simulation intervals of 5 ns, and the first 10 ns of each run were
neglected. The subdomain numbering is given by the black arrows below the x-axis. The blue squares show the residues constituting the latrunculin
binding site, that is, those residues with at least 50% of atoms within 5.0 A˚ of any atom of the inhibitor or residues forming a hydrogen bond to
latrunculin in the 1ESV crystal structure (residues Gly15, Leu16, Pro32, Ile34, Gln59, Tyr69, Asp157, Gly182, Arg183, Thr186, Arg206, Glu207, and
Arg210). (Bottom left and right) RMSF of Ca atoms in A˚ (black and red line, respectively, with y-axis on the left) and the crystallographic B-factors
(blue and magenta dots, respectively, with y-axis on the right) for ATP–actin (bottom left) and latr.–ATP–actin (bottom right). Crystal contacts are
shown by green squares for residues with one or more heavy atoms closer than 5 A˚ to heavy atoms of neighboring proteins in the crystal. [Color
figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Figure 2
Stability of latrunculin binding mode along MD simulations. (Top) Two-dimensional scheme of latrunculin A and G-actin residues involved in
hydrogen bonds. (Middle and bottom) Time series of hydrogen bond distances, that is, the distance between donor and acceptor atoms. The colors
are consistent with those used in the top panel. The individual MD runs are separated by black vertical lines. Note the different y-axis range for the
hydrogen bond to Glu214, which is water mediated.
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removal of profilin.26,27 Recent MD studies of the Oda
model19 and the latest Holmes model22 of F-actin indi-
cate that the interdomain twist of F-actin increases
slightly during the simulations.22,28 However, the twist
angle still remains significantly smaller than in G-actin
simulations for both models. In recent MD simula-
tions,26 a ‘‘superclosed’’ G-actin conformation was
observed, which resembles the structure in F-actin mod-
els.19–22 Furthermore, water molecules in the nucleotide
binding site have been shown to influence actin confor-
mation in MD simulations.29 The influence of the natu-
ral product phalloidin on the actin filament has been
investigated by explicit solvent MD simulations.28 Inter-
estingly, during these simulations a displacement was
observed from the original position proposed by the
experimentalists toward a site with more adjacent inter-
strand contacts between subunits along the short-pitch
helix, which is congruent with the filament stiffening
effect of phalloidin.28
As of today, no computational study of the effect of
latrunculin on the dynamical properties of G-actin has
been reported. Here, we investigate the motional correla-
tion between subdomains in monomeric actin and the
influence of latrunculin on the relative rotation of the
two major domains by explicit solvent MD simulations.
Three systems are investigated in detail: apo actin, ATP-
bound actin, and ATP-bound actin in complex with
latrunculin A. Multiple MD runs for each system are car-
ried out for a total simulation time of about 1.2 ls. Sim-
ulations of nucleotide-free actin indicate a higher inter-
domain rotational flexibility compared to the ATP-bound
state, which is congruent with the observation that nucle-
otide-free actin polymerizes more favorably than ATP–
actin.30 Moreover, the simulations in the presence of
latrunculin show that binding of this natural product
prevents the relative rotation of the two major domains,
which is necessary for the G- to F-transition, thus inter-
fering with actin polymerization.
MATERIALS ANDMETHODS
Preparation of the structures
The coordinates of the inhibitor-free31 and -bound9
actin were downloaded from the PDB database (PDB ID:
1EQY and 1ESV, respectively). As residues 1–5 are miss-
ing in the X-ray structures, the COCH3 group was
added to the N-terminal Thr6. The C-termini were con-
sidered negatively charged.
Due to the high flexibility of the D-loop, the coordi-
nates of its residues are not present in the PDB files (res-
idues 40–49 in 1EQY and 40–50 in 1ESV). As in previ-
ously published MD studies of G-actin,23–25,29 initial
D-loop coordinates were obtained from an actin crystal
structure with the D-loop residues resolved. Using
SWISS-MODEL,32 the PDB structure 3DAW was selected
as template for the two following reasons. First, the
1EQY and 1ESV coordinate sets are ATP-bound actin
structures, which is also the case for 3DAW. Second, in
3DAW, the protein used for cocrystallization (which is a
domain of twinfilin) binds between the actin Subdomains
1 and 3, which are located far away from the D-loop,
and thus the presence of the twinfilin domain does not
directly influence the conformation of the D-loop. Simi-
lar to the procedure described in Ref. 24, after fitting the
crystal structures (1EQY and 1ESV) to the template using
the Ca atoms present in all structures, the missing coor-
dinates of the D-loop were taken from the template and
inserted into the 1EQY and 1ESV structure. To relax
elongated bonds after the coordinate transfer, an energy
minimization of 100 steps of the steepest descent and
1000 steps of the adopted basis Newton–Raphson algo-
rithm was carried out using the program CHARMM33,34
and the CHARMM22 force field.35 During the minimi-
zation, all coordinates present in the X-ray structures
were kept fixed. Note that in this study, the coordinates
of the D-loop are not used for structural alignment or
calculation of root mean square deviation (RMSD). As
there is no crystal structure of the ATP-free actin avail-
able, the coordinates of ATP and the associated calcium
ion were removed from the 1EQY structure. The result-
ing structure is referred to as ‘‘apo actin.’’
MD simulations
To reproduce neutral pH conditions, the side chains of
aspartates and glutamates were negatively charged, those
of lysines and arginines were positively charged, and his-
tidines were considered neutral. The protein was
immersed in an orthorhombic box of pre-equilibrated
water molecules. The size of the box was chosen to have
a minimal distance of 13 A˚ between the boundary and
any atom of the protein. VMD36 was used for setting up
the simulation system, while minimization, heating, and
production runs were performed with NAMD37 AQ2using
the CHARMM22 force field35 and the TIP3P model of
water. For the parameters of latrunculin A, the CGenFF
force field38 was used. Periodic boundary conditions
were applied, and the particle-mesh Ewald approach39
was used for the long-range electrostatics. The van der
Waals interactions were truncated at a cutoff of 12 A˚,
and a switch function was applied starting at 10 A˚. The
MD simulations were carried out at constant temperature
(298 K) and constant pressure (1 atm) with a time step
of 2 fs using the SHAKE algorithm40 to fix the length of
covalent bonds involving hydrogen atoms.
Twist angle
Twist angles between Domains 1 and 2 were calculated
as described in Ref. 41, where the twist angle is defined
as the angle between two planes, one containing the Ca
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atom of residue Gly55 (Subdomain 2) and the axis of
rotation, the other containing Glu207 (Subdomain 4) and
the axis of rotation. Each MD snapshot was superimposed
to the monomeric ADP–actin structure (PDB ID 1J6Z).41
The axis of rotation was determined between 1J6Z and the
F-actin subunit (PDB ID 2ZWH) using DynDom.42 In
addition to the twist angle, time series of the dihedral
angle between the centers of mass of the four subdomains
(also called ‘‘propeller angle’’26) were computed. The pro-
peller angle time series are very similar to the twist angle
time series and therefore not shown.
Motional correlations fromMD trajectories
Normalized fluctuation correlations between pairs of
Ca atoms were calculated using the DCC43 algorithm as
implemented in WORDOM [see Eq. (10) in Ref. 44].
Their values range from 21 (for a fully anticorrelated
motion between two Ca atoms, i.e., motion in opposite
direction) through 0 (indicating no correlation) to 11
(for a fully correlated motion).
The linear mutual information (LMI)45,46 algorithm
was utilized as a second method to compute motional
correlations [see Eq. (11) in Ref. 44. LMI values vary
from 0 indicating lack of any correlation to 11, which is
complete correlation between atomic displacements.
Anticorrelation is not captured by the mutual informa-
tion measure. Correlations between perpendicular
motions are estimated by the LMI but not the DCC
method.
It should be noted that the motional correlations
depend strongly on the choice of atoms and reference
frame for alignment prior to the correlation analysis. The
Ca atoms of Domain 1, excluding residues 40–50, were
utilized for the alignment to measure the degree of intra-
domain correlation of Domain 2. The average structure
calculated from the MD trajectories was used as reference
frame for each system. To test the robustness of the
choice of reference frame, the first 20 ns of each trajec-
tory were removed, and the average structure recalcu-
lated. Using the resulting structure as reference, frame led
to essentially identical covariance matrices.
Accession numbers
The structures used in this study were obtained from
the PDB database under accession codes 1EQY, 1ESV,
1J6Z, 2ZWH, and 3DAW.
RESULTS AND DISCUSSION
ATP-bound G-actin is considered as reference and
most of the analysis focuses on the differences with
respect to this system referred to as ‘‘ATP-actin.’’ The tri-
partite complex is called ‘‘latr.–ATP–actin’’ and the nucle-
otide-free G-actin is called ‘‘apo actin.’’ When ‘‘F-actin’’
is mentioned, the Oda model19 is referred to. Table T1I
gives an overview of the performed MD simulations.
Overall stability and flexibility
The low values of the Ca RMSD from the X-ray struc-
ture of G-actin used as starting conformation indicate that
the overall structural stability is preserved in all MD runs
(Supporting Information, Fig. S1). Although apo actin
denatures in solution,47 its stability is preserved for the
entire duration of the MD simulations. Apo actin was also
found to be stable in a previously published MD simula-
tion of 8 ns.25 As the rate constant of the denaturation is
0.2 s21,47 unfolding is not expected to occur even in the
100 ns time scale of the present MD simulations. There is
a good correlation between the root mean square fluctua-
tion (RMSF) of the Ca atoms along the MD simulations
and the crystallographic temperature factors for ATP–actin
(Fig. 1). The low RMSD values and reasonable fluctua-
tions indicate that the force field and simulation protocol
are adequate for investigating the dynamical properties of
G-actin. The nearly perfect overlap of the calculated
RMSF of ATP–actin and latr.–ATP–actin (Fig. 1, top right)
suggests that latrunculin influences marginally the fluctua-
tions of the actin backbone on the nanosecond time scale.
Thus, the higher B-factors for the latr.–ATP–actin complex
than in the absence of latrunculin, particularly for Subdo-
main 4, might originate from disorder in the crystal of the
former. In all MD runs, the highest mobility is observed
for the D-loop (residues 40–50) in Subdomain 2, which is
the most flexible part of G-actin, and residues 220–250 in
Subdomain 4, in agreement with recently published MD
results of the ADP-bound state.22 The absence of ATP
does not have a strong effect on the Ca RMSF either
(Supporting Information, Fig. S2).
It is interesting to analyze the stability of the latruncu-
lin binding mode. Latrunculin stays in its binding site
for the entire duration of the MD simulations as shown
by the RMSD time series of the heavy atoms of latruncu-
lin that oscillate between 1 and 2.5 A˚ during most of the
runs (Supporting Information, Fig. S3). Moreover, the
two intermolecular hydrogen bonds between the thiazoli-
dinone ring of latrunculin and the side chains of Asp157
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Table I
Summary of Performed MD Simulations
System
Starting str.
(PDB ID)
Latrunculin
presence
ATP
presence
No. of
runsa Length (ns)b
ATP–actin 1EQY No Yes 4 152, 136, 91, 89
Latr.–ATP–actin 1ESV Yes Yes 4 158, 152, 75, 80
Apo actinc 1EQY No No 2 80, 77
aMultiple runs were started using different seeds to generate a random distribu-
tion of the initial velocities.
bThe different lengths of the individual runs are due to manual stopping after the
first 150 ns or 75 ns.
cSince no crystal structure of ATP-free actin is available, the coordinates of ATP
and the associated calcium ion were removed from the 1EQY structure.
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and Thr186 are stable (Fig. 2). A slightly lower stability
is observed for the hydrogen bonds between the tetrahy-
dropyran moiety and the side chains of Tyr69 and
Arg210, while the water-bridged hydrogen bond between
the lactone carbonyl and the side chain of Glu214 shows
relatively strong fluctuations.
Evidence for the hindrance of interdomain
rotation by latrunculin
The relative motion between domains can be measured
by the RMSD from G-actin and F-actin after overlap of
the Ca atoms of Domain 1. In contrast to ATP–actin,
only a negligible number of MD snapshots have a RMSD
from F-actin below 4 A˚ in the latrunculin-bound form
(Fig.F3 3, middle). The contrast is even more pronounced
between latr.–ATP–actin and apo actin. The percentage
of MD snapshots with a RMSD from F-actin below 3.5 A˚
is 4.7, 4.4, and 0% for apo actin, ATP–actin, and latr.–
ATP–actin, respectively. Using a threshold of 4 A˚ the cor-
responding values are 15.1, 11.6, and 0.3%. These simu-
lation results suggest that latrunculin binding decreases
the probability of the protein adopting an F-actin-like
conformation, whereas the absence of ATP increases the
probability. The anticorrelation between the RMSD from
G- and F-actin suggests that a conformational change
increasing the deviation from G-actin augments also the
structural similarity to the conformation observed in the
filament. According to Figure 3, the degree of anticorrela-
tion for the three investigated systems is the lowest for
latr.–ATP–actin and the highest for apo actin. Thus, the
presence of latrunculin interferes with the structural rear-
rangements required for polymerization.
Another interesting measure of the relative motion of the
two domains in the MD trajectories is the fluctuation cor-
relation between pairs of residues, which was computed
with two different methods (Fig.F4 4). In contrast to the
dynamic cross correlation (DCC) method, the LMI algo-
rithm is able to estimate correlations between perpendicular
motions (see ‘‘Materials and Methods’’ section). For ATP–
actin a high degree of correlated movement is observed
within the major Domain 2, which indicates that Domain
2 moves almost as a rigid body with respect to Domain 1.
While the fluctuations of some segments, for example, resi-
dues 157–172 and 275–292, appear uncorrelated to the
movement of a large part of Domain 2 according to the
DCC results, using the LMI method reveals a high degree
of correlation and suggests a perpendicular movement of
these residues with respect to a large number of residues in
Domain 2. The matrix of difference of motional correlation
(Fig. 4, bottom) shows a reduced intradomain correlation
for Domain 2 in the presence of latrunculin, indicating that
Domain 2 moves to a lesser extent as a rigid body relative
to Domain 1 in the latrunculin complex.
The relative rotation of the two main domains can
also be monitored by the twist angle (Fig.F5 5), which is
defined as the angle between two planes intersecting at
the axis of rotation, with one plane containing the Ca
atom of residue Gly55 (Subdomain 2) and the other con-
taining the Ca atom of Glu207 (Subdomain 4).41 The
twist angle in F-actin is 88, and it ranges between 16 and
258 in G-actin (depending on the crystal structure) with
an average of 208. Overall, higher twist angles are
observed for latr.–ATP–actin than for ATP–actin. In the
simulations of the latter, there are several events where
the twist angle is almost reduced to the value in F-actin
or even further, resulting in a flattened structure similar
to the conformation in the filament. As an example, in
the time interval 75–97 ns of the second run of the ATP–
actin simulations the twist angle is close to the one of F-
actin (Fig. 5(b)]. Note also that during this time interval,
the RMSD from F-actin and G-actin after superposition
of the Ca atoms of Domain 1 (Supporting Information,
Fig. S4) are approximately equal. A flat conformation of
ATP-bound G-actin has also been observed in 4 out of
20 explicit water MD simulations in a previous study
(where it was called a ‘‘superclosed’’ state).26 The authors
suggested that the superclosed state is not the predomi-
nant form of ATP–actin in equilibrium, which is a plau-
sible reason why this state has not been observed crystal-
lographically. In contrast to the flattening observed in the
absence of latrunculin, over the entire course of the four
MD runs of latr.–ATP–actin, the twist angle remained
close to or even higher than the one of G-actin. Thus,
latrunculin binding to monomeric actin prevents the rel-
ative rotation of the two major domains required for the
polymerization process. Interestingly, there are simulation
segments during which an increase in RMSD from both
G- and F-actin relative to the simulation average (Sup-
porting Information, Fig. S1) correlates with an increase
in twist angle (e.g., the time intervals 80–90 ns in the
first run of ATP–actin, 3–10 ns and 17–24 ns in the
fourth run of latr.–ATP–actin, and 33–39 ns in the first
run of apo actin). Here, the two major domains of actin
rotate in the opposite direction compared to the flatten-
ing in the G- to F-actin transition.
Finally, the interdomain rotation occurs most fre-
quently in simulations of apo actin. There are more flat-
tening events in the simulations of the nucleotide-free
structure than in those of ATP–actin, though the former
sampling is only about one-third of the latter. Moreover,
twist angle values of about 58 are reached only in the ab-
sence of ATP. These findings suggest that ATP slightly
hinders the relative displacements of the two main
domains of G-actin.
CONCLUSIONS
Explicit solvent MD simulations of monomeric actin in
the presence and absence of latrunculin have been carried
out to study the influence of the binding of this natural
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Figure 3
Deviation of MD snapshots from G-actin and F-actin. Scatter plots of RMSD from G- and F-actin, calculated for Ca atoms of Domain 2 upon
overlap of Ca atoms of Domain 1 (excluding residues 40–50 of the flexible D-loop), using the structure 2ZWH as reference for F-actin. (a) ATP–
actin, (b) latr.–ATP–actin, and (c) apo actin. The reference structure for G-actin is 1EQY in (a) and (c) and 1ESV in (b). For better visibility, MD
Runs 3 and 4 are shown separately from Runs 1 and 2 in (a) and (b). [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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product on the plasticity of G-actin. The simulation results
provide evidence that latrunculin prevents actin polymeriza-
tion by hindering the rotation of the two major domains
associated with the G- to F-actin transition. Time series of
the twist angle show no substantial flattening for latr.–ATP–
actin in contrast to simulations of ATP–actin and apo actin.
Moreover, cross correlations of atomic displacements indi-
cate a lower degree of rigid body movement of the two
domains relative to each other upon binding of latrunculin.
The rotational flexibility of the two domains in G-actin
increases in the following order for the three investigated
systems: latr–ATP–actin  ATP–actin < apo actin.
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Figure 4
Latrunculin reduces correlated displacement of Domain 2 versus Domain 1. Motional correlations from MD trajectories of ATP–actin (top) and
latr.–ATP–actin (middle) calculated by the DCC (left panels) and LMI (right panels) algorithm. The Ca atoms of Domain 1 (excluding the D-loop)
were superimposed prior to the correlation analysis. The color scale ranges from blue (anticorrelation) to white (no correlation) to red (correlation)
for the DCC algorithm and from white (no correlation) to red (correlation) for the LMI method. The subdomain numbering is given by the black
arrows. Note that the two algorithms give similar qualitative results and in particular weaker correlation within the major Domain 2, that is,
Subdomains 3 and 4, in the presence of latrunculin. The differences between the two algorithms, and in particular the higher correlation reported
by LMI than DCC, originate from the fact that only LMI takes into account correlated perpendicular motion.44 (Bottom) Difference between
covariance matrices of latr.–ATP–actin and ATP–actin.
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This conclusion is consistent with the experimental obser-
vations that nucleotide-free actin polymerizes more easily
than ATP-bound actin,30 whereas latrunculin-bound actin
is not able to polymerize.9
Considering that both ATP and latrunculin bind in a
cleft between the two major domains of monomeric
actin, the MD results seem plausible: the domains are
able to rotate more freely, when their relative movement
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Figure 5
Twist angle analysis shows that latrunculin prevents interdomain motion. (a) Side view on Subdomains 3 and 4 of three selected snapshots (green,
red, and yellow) from the ATP–actin runs after superposition of Ca atoms of Subdomains 1 and 2 (colored in gray) excluding the D-loop. The
arrow illustrates the relative rotation of Subdomain 4. The axis of rotation passes through Subdomains 1 and 3 (not shown). (b) Twist angle time
series of ATP–actin (top), latr.–ATP–actin (middle), and apo actin (bottom). The three colored circles in the ATP–actin time series correspond to
the three snapshots shown in (a). The blue horizontal line shows the mean value of the twist angle measured on 83 crystal structure of G-actin,
whereas the green horizontal line indicates the twist angle in the F-actin structure of the Oda model.19 The individual MD runs are separated by
black vertical lines.
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is not restricted by the binding of ligands. The inhibitory
mechanism of latrunculin proposed here on the basis of
the MD simulations could be verified experimentally by
mutating one or more of the actin side chains in contact
with latrunculin into bulkier ones, for example,
Leu16Trp, Ile34Trp, and/or Tyr69Trp. Finally, motivated
by the MD simulation results, we are currently carrying
out de novo design48 of small molecules that bind in the
same cleft as latrunculin as potential anti-cancer
compounds.
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Conclusions
Actin, a protein that plays a pivotal role in the functioning of eukaryotic cells, was the focus
of the present thesis. The only compounds known to bind to actin are structurally complex
natural products or analogues thereof, which are difficult to synthesize or extract from natural
sources.
To identify new lead structures for the design of novel actin inhibitors, a virtual screening
campaign of natural product-derived compounds was carried out targeting the binding site at
the so-called pointed end of actin. The binding behavior of top-ranking compounds selected by
consensus scoring was investigated by molecular dynamics (MD) simulations. Those molecules
consistently found to unbind within a few nanoseconds in multiple independent MD runs were
discarded as leads, in accordance with the assumption that low unbinding times correlate with
poor binding affinities. The applied approach is useful to eliminate molecules with a low chance
to bind at an early stage of a drug discovery program. The lack of accuracy of scoring functions
remains one of the principle limitations of virtual high-throughput docking; even the use of
multiple scoring functions, as in this study, does not guarantee that only high-affinity binders are
selected. MD simulations allow molecules predicted to have high binding affinities by docking to
be discarded if their binding modes are unstable in MD. This way, time-consuming experiments
are avoided for molecules having poor binding affinities.
A single exponential behavior was observed for the kinetics of ligand unbinding, indicating
the existence of one predominant free energy barrier, the barrier of unbinding. The free energy
barriers between different binding modes are much lower [1]. A small number of compounds
were identified with relatively stable binding behavior and high unbinding times, suggesting
a binding affinity within the micromolar range and their potential as lead compounds in the
design of novel actin inhibitors.
The binding behavior of one of the top-ranking compounds selected by consensus scoring
was optimized by performing chemical modifications according to the most populated structural
clusters in the MD simulations. Addition of only two heavy atoms resulted in a significant
increase in the stability of the most populated binding mode, indicating a higher binding affinity
of the optimized relative to the original compound.
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In chapter 3, putative actin inhibitors were identified using de novo design, another method
for computer-aided drug design where molecules are built “from scratch”. The thiazolidinone
moiety of latrunculin was used as an anchor from which additional fragments were grown, and
compounds forming hydrogen bonds analogous to latrunculin and more favorable van der Waals
interaction efficiencies were identified.
In vitro assays of the compounds obtained from the virtual screening and the de novo design
campaigns are currently being performed at the Department of Organic Chemistry at the Uni-
versity of Zu¨rich to determine their binding affinity and ability to inhibit actin polymerization.
In chapter 4, MD simulations were carried out to investigate a basic research question: the
mechanism by which the natural product latrunculin inhibits actin polymerization. As recently
shown by X-ray fiber diffraction [2], the propeller-like twist of monomeric actin is flattened in
the G- to F-actin transition by an interdomain rotation of appr. 20 degrees. The MD study
presented in chapter 4 provides evidence that latrunculin prevents this conformational change,
thereby inhibiting actin polymerization. The presence of latrunculin reduces the extent of rigid
body movement of the two major domains relative to one another as shown by normalized
fluctuation correlations. Furthermore, measuring the degree of twist between the two actin
domains over the course of the MD simulations showed no substantial flattening of actin in the
presence of latrunculin. In contrast, in absence of latrunculin, the interdomain rotation was
observed for ATP-bound actin and even more frequently for ATP-free actin. The simulation
results are consistent with the experimentally observed higher tendency of nucleotide-free actin
to polymerize [3].
The most significant piece of the puzzle still missing in actin research today is the struc-
ture of F-actin at an atomistic level. Detailed knowledge of the structural differences between
normal and malignantly transformed actin filaments would allow the design of inhibitors with
a high selectivity for actin in tumor cells and avoid side effects related to targeting cytoskeletal
components of both normal and cancer cells, such as observed for the microtubule-targeting
chemotherapy agent Taxol.
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